Johnson & Johnson (JNJ) 10-Q 27 Oct 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Oct. 02, 2022	Oct. 21, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 02, 2022
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,614,483,607
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-01
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Oct. 02, 2022	Jan. 02, 2022
Current assets:
Cash and cash equivalents	$ 11,355	$ 14,487
Marketable securities	22,724	17,121
Accounts receivable, trade, less allowances $201 (2021, $230)	15,890	15,283
Inventories (Note 2)	11,675	10,387
Prepaid expenses and other	3,592	3,701
Total current assets	65,236	60,979
Property, plant and equipment at cost	46,681	47,679
Less: accumulated depreciation	(28,529)	(28,717)
Property, plant and equipment, net	18,152	18,962
Intangible assets, net (Note 3)	40,336	46,392
Goodwill (Note 3)	33,383	35,246
Deferred taxes on income (Note 5)	9,392	10,223
Other assets	8,625	10,216
Total assets	175,124	182,018
Current liabilities:
Loans and notes payable	4,424	3,766
Accounts payable	10,153	11,055
Accrued liabilities	11,953	13,612
Accrued rebates, returns and promotions	14,021	12,095
Accrued compensation and employee related obligations	3,006	3,586
Accrued taxes on income (Note 5)	1,986	1,112
Total current liabilities	45,543	45,226
Long-term debt (Note 4)	27,603	29,985
Deferred taxes on income (Note 5)	4,946	7,487
Employee related obligations (Note 6)	8,353	8,898
Long-term taxes payable (Note 5)	4,162	5,713
Other liabilities	9,918	10,686
Total liabilities	100,525	107,995
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(15,292)	(13,058)
Retained earnings	127,917	123,060
Less: common stock held in treasury, at cost (502,961,000 and 490,878,000 shares)	41,146	39,099
Total shareholders’ equity	74,599	74,023
Total liabilities and shareholders' equity	$ 175,124	$ 182,018

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Oct. 02, 2022	Jan. 02, 2022
Current assets:
Allowances for doubtful accounts	$ 201	$ 230
Shareholders' equity:
Common stock, par value per share (per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock, shares (in shares)	502,961,000	490,878,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Income Statement [Abstract]
Sales to customers	$ 23,791	$ 23,338	$ 71,237	$ 68,971
Sales to customers percent to sales	100%	100%	100%	100%
Cost of products sold	$ 7,807	$ 7,250	$ 23,324	$ 21,900
Cost of products sold percent to sales	32.80%	31.10%	32.70%	31.80%
Gross profit	$ 15,984	$ 16,088	$ 47,913	$ 47,071
Gross Profit Percent To Sales	67.20%	68.90%	67.30%	68.20%
Selling, marketing and administrative expenses	$ 6,089	$ 6,000	$ 18,253	$ 17,505
Selling marketing and administrative expenses percent to sales	25.60%	25.70%	25.70%	25.40%
Research and development expense	$ 3,597	$ 3,422	$ 10,762	$ 9,994
Research and development expense percent to sales	15.10%	14.70%	15.10%	14.50%
In-process research and development	$ 0	$ 900	$ 610	$ 900
In-process research and development percent to sales	0%	3.90%	0.90%	1.30%
Interest income	$ (150)	$ (13)	$ (236)	$ (40)
Interest income percent to sales	(0.60%)	(0.10%)	(0.30%)	(0.10%)
Interest expense, net of portion capitalized	$ 51	$ 20	$ 99	$ 123
Interest expense, net of portion capitalized percent to sales	0.20%	0.10%	0.10%	0.20%
Other (income) expense, net	$ 493	$ 1,850	$ 664	$ 480
Other (income) expense, net percent to sales	2.10%	7.90%	0.90%	0.70%
Restructuring (Note 12)	$ 82	$ 60	$ 237	$ 169
Restructuring charge percent to sales	0.30%	0.20%	0.30%	0.20%
Earnings before provision for taxes on income	$ 5,822	$ 3,849	$ 17,524	$ 17,940
Earnings before provision for taxes on income percent to sales	24.50%	16.50%	24.60%	26%
Provision for taxes on income (Note 5)	$ 1,364	$ 182	$ 3,103	$ 1,798
Provision for taxes on income percent to sales	5.80%	0.80%	4.40%	2.60%
Net earnings	$ 4,458	$ 3,667	$ 14,421	$ 16,142
Net earnings percent to sales	18.70%	15.70%	20.20%	23.40%
NET EARNINGS PER SHARE
Basic (per share)	$ 1.70	$ 1.39	$ 5.49	$ 6.13
Diluted (per share)	$ 1.68	$ 1.37	$ 5.41	$ 6.04
AVG. SHARES OUTSTANDING
Basic (shares)	2,627.9	2,632.6	2,628.9	2,632.2
Diluted (shares)	2,661.3	2,674.9	2,667.5	2,674.6

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 4,458	$ 3,667	$ 14,421	$ 16,142
Other comprehensive income (loss), net of tax
Foreign currency translation	(1,252)	(382)	(1,957)	(241)
Securities:
Unrealized holding gain (loss) arising during period	(2)	0	(35)	(1)
Reclassifications to earnings	0	0	0	0
Net change	(2)	0	(35)	(1)
Employee benefit plans:
Prior service cost amortization during period	(37)	(40)	(110)	(122)
Gain (loss) amortization during period	151	273	454	822
Net change	114	233	344	700
Derivatives & hedges:
Unrealized gain (loss) arising during period	(204)	67	(254)	(55)
Reclassifications to earnings	(105)	(233)	(332)	(576)
Net change	(309)	(166)	(586)	(631)
Other comprehensive income (loss)	(1,449)	(315)	(2,234)	(173)
Comprehensive income	$ 3,009	$ 3,352	$ 12,187	$ 15,969

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Statement of Comprehensive Income [Abstract]
Foreign Currency Translation	$ (181)	$ (86)	$ (859)	$ (315)
Securities			(9)
Employee Benefit Plans	(33)	(65)	(98)	(197)
Derivatives & Hedges	$ (82)	$ (43)	$ (155)	$ (167)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Jan. 03, 2021	$ 63,278	$ 113,890	$ (15,242)	$ 3,120	$ (38,490)
Net earnings	16,142	16,142
Cash dividends paid	(8,241)	(8,241)
Employee compensation and stock option plans	1,726	(699)			2,425
Repurchase of common stock	(2,460)				(2,460)
Other comprehensive income (loss), net of tax	(173)		(173)
Ending Balance at Oct. 03, 2021	70,272	121,092	(15,415)	3,120	(38,525)
Beginning Balance at Jul. 04, 2021	69,580	120,154	(15,100)	3,120	(38,594)
Net earnings	3,667	3,667
Cash dividends paid	(2,791)	(2,791)
Employee compensation and stock option plans	522	62			460
Repurchase of common stock	(391)				(391)
Other comprehensive income (loss), net of tax	(315)		(315)
Ending Balance at Oct. 03, 2021	70,272	121,092	(15,415)	3,120	(38,525)
Beginning Balance at Jan. 02, 2022	74,023	123,060	(13,058)	3,120	(39,099)
Net earnings	14,421	14,421
Cash dividends paid	(8,728)	(8,728)
Employee compensation and stock option plans	1,832	(836)			2,668
Repurchase of common stock	(4,715)				(4,715)
Other comprehensive income (loss), net of tax	(2,234)		(2,234)
Ending Balance at Oct. 02, 2022	74,599	127,917	(15,292)	3,120	(41,146)
Beginning Balance at Jul. 03, 2022	76,357	126,216	(13,843)	3,120	(39,136)
Net earnings	4,458	4,458
Cash dividends paid	(2,970)	(2,970)
Employee compensation and stock option plans	368	213			155
Repurchase of common stock	(2,165)				(2,165)
Other comprehensive income (loss), net of tax	(1,449)		(1,449)
Ending Balance at Oct. 02, 2022	$ 74,599	$ 127,917	$ (15,292)	$ 3,120	$ (41,146)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 1.13	$ 1.06	$ 3.32	$ 3.13

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 14,421	$ 16,142
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	5,198	5,547
Stock based compensation	925	920
Asset write-downs	787	964
Net gain on sale of assets/businesses	(213)	(601)
Deferred tax provision	(2,488)	(2,564)
Credit losses and accounts receivable allowances	(14)	(60)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(1,591)	(1,818)
Increase in inventories	(1,877)	(1,178)
Increase in accounts payable and accrued liabilities	141	182
Decrease in other current and non-current assets	4,563	2,082
Decrease in other current and non-current liabilities	(4,008)	(1,938)
NET CASH FLOWS FROM OPERATING ACTIVITIES	15,844	17,678
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(2,422)	(2,237)
Proceeds from the disposal of assets/businesses, net (Note 10)	322	666
Acquisitions, net of cash acquired (Note 10)	(522)	0
Purchases of investments	(31,163)	(18,843)
Sales of investments	26,324	16,809
Credit support agreements activity, net	(305)	696
Other (primarily licenses and milestones)	(208)	(414)
NET CASH USED BY INVESTING ACTIVITIES	(7,974)	(3,323)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(8,728)	(8,241)
Repurchase of common stock	(4,715)	(2,460)
Proceeds from short-term debt	7,099	1,283
Repayment of short-term debt	(4,808)	(821)
Proceeds from long-term debt, net of issuance costs	1	3
Repayment of long-term debt	(2,133)	(1,452)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	907	808
Credit support agreements activity, net	1,678	168
Other	128	101
NET CASH USED BY FINANCING ACTIVITIES	(10,571)	(10,611)
Effect of exchange rate changes on cash and cash equivalents	(431)	(125)
(Decrease)/Increase in cash and cash equivalents	(3,132)	3,619
Cash and Cash equivalents, beginning of period	14,487	13,985
CASH AND CASH EQUIVALENTS, END OF PERIOD	11,355	17,604
Acquisitions
Fair value of assets acquired	620	0
Fair value of liabilities assumed and noncontrolling interests	(98)	0
Net cash paid for acquisitions	$ 522	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 02, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended October 2, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. Recently Adopted Accounting Standards There were no new material accounting standards adopted in the fiscal third quarter of 2022. Recently Issued Accounting Standards Not Adopted as of October 2, 2022 ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) – Disclosure of Supplier Finance Program Obligations This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity’s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Inventories

Inventories	9 Months Ended
	Oct. 02, 2022
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) October 2, 2022 January 2, 2022 Raw materials and supplies $ 1,730 1,592 Goods in process 2,106 2,287 Finished goods 7,839 6,508 Total inventories $ 11,675 10,387

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Oct. 02, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) October 2, 2022 January 2, 2022 Intangible assets with definite lives: Patents and trademarks — gross (1) $ 35,132 38,572 Less accumulated amortization (20,116) (20,088) Patents and trademarks — net 15,016 18,484 Customer relationships and other intangibles — gross 22,302 23,011 Less accumulated amortization (12,406) (11,925) Customer relationships and other intangibles — net (2) 9,896 11,086 Intangible assets with indefinite lives: Trademarks 6,648 6,985 Purchased in-process research and development (3) 8,776 9,837 Total intangible assets with indefinite lives 15,424 16,822 Total intangible assets — net $ 40,336 46,392 (1) The change in intangible assets with definite lives is primarily the result of currency translation effects. (2) The majority is comprised of customer relationships (3) In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives. In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2 billion in the fiscal fourth quarter related to this impairment. The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020. Goodwill as of October 2, 2022 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical MedTech Total Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246 Goodwill, related to acquisitions — — 195 195 Currency translation/Other (1,037) (920) (101) (2,058) Goodwill at October 2, 2022 $ 8,773 9,660 14,950 33,383 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.0 billion and $1.1 billion for the fiscal third quarters ended October 2, 2022 and October 3, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $3.2 billion and $3.6 billion for the fiscal nine months ended October 2, 2022 and October 3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2022 2023 2024 2025 2026 $4,300 4,300 4,100 3,400 2,800 See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 02, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 2, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $0.8 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $47.1 billion, $36.2 billion and $10.0 billion, respectively. As of January 2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion, $37.4 billion and $10.0 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of October 2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $922 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2022 and 2021, net of tax: October 2, 2022 October 3, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (322) — — — — (62) — Derivatives designated as hedging instruments — — — 322 — — — — 62 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 13 — — — — 34 — Amount of gain or (loss) recognized in AOCI — — — 13 — — — — 34 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (20) (83) 53 — 22 (3) 58 8 — 19 Amount of gain or (loss) recognized in AOCI (45) (94) 91 — 36 (35) (155) 37 — 42 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 120 — — — 117 — Amount of gain or (loss) recognized in AOCI $ — — — (205) — — — — 144 — The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2022 and 2021, net of tax: October 2, 2022 October 3, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (1,094) — — — — (56) — Derivatives designated as hedging instruments — — — 1,094 — — — — 56 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 102 — — — — 115 — Amount of gain or (loss) recognized in AOCI — — — 102 — — — — 115 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (54) (141) 118 — (35) 25 106 (1) — 24 Amount of gain or (loss) recognized in AOCI (48) (153) 193 — (75) (41) (398) 80 — 67 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 342 — — — — 307 — Amount of gain or (loss) recognized in AOCI $ — — — (273) — — — — 122 — As of October 2, 2022, and January 2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) October 2, 2022 January 2, 2022 October 2, 2022 January 2, 2022 Long-term Debt $ 8,668 9,793 (1,430) (142) The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2022 and 2021: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Foreign Exchange Contracts Other (income) expense $ 109 (13) 211 (50) The following table is the effect of net investment hedges for the fiscal third quarters ended in 2022 and 2021: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Debt $ 208 115 Interest (income) expense — — Cross Currency interest rate swaps $ 261 141 Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal nine months ended in 2022 and 2021 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Debt $ 478 279 Interest (income) expense — — Cross Currency interest rate swaps $ 1,134 432 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: (Dollars in Millions) January 2, 2022 October 2, 2022 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,884 (607) (755) 522 522 Equity Investments without readily determinable value $ 500 (29) 60 531 531 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, there was a decrease of $29 million in the fair value reflected in net income as a result of impairments. In the fiscal third quarter ended October 2, 2022, the Company sold all its equity investments in argenx SE for proceeds of $0.6 billion. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of October 2, 2022 and January 2, 2022 were as follows: October 2, 2022 January 2, 2022 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 1,942 — 1,942 540 Interest rate contracts (2) — 2,533 — 2,533 796 Total — 4,475 — 4,475 1,336 Liabilities: Forward foreign exchange contracts — 1,881 — 1,881 881 Interest rate contracts (2) — 1,884 — 1,884 979 Total — 3,765 — 3,765 1,860 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 178 — 178 24 Liabilities: Forward foreign exchange contracts — 68 — 68 28 Other Investments: Equity investments (3) 522 — — 522 1,884 Debt securities (4) — 22,124 — 22,124 19,727 Other Liabilities Contingent consideration (5) $ — — 525 525 533 Gross to Net Derivative Reconciliation October 2, 2022 January 2, 2022 (Dollars in Millions) Total Gross Assets $ 4,653 1,360 Credit Support Agreement (CSA) (4,440) (1,285) Total Net Asset 213 75 Total Gross Liabilities 3,833 1,888 Credit Support Agreement (CSA) (3,636) (1,855) Total Net Liabilities $ 197 33 Summarized information about changes in liabilities for contingent consideration for each of the fiscal nine months ended is as follows: October 2, 2022 October 3, 2021 (Dollars in Millions) Beginning Balance $ 533 $ 633 Changes in estimated fair value (6) (85) 28 Additions 89 — Payments (12) (48) Ending Balance $ 525 $ 613 (1) 2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Includes $507 million and $520 million, classified as non-current other liabilities as of October 2, 2022 and January 2, 2022, respectively. Includes $18 million and $13 million classified as current liabilities as of October 2, 2022 and January 2, 2022, respectively. (6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. The Company's cash, cash equivalents and current marketable securities as of October 2, 2022 comprised: (Dollars in Millions) Carrying Amount Gain/( Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 4,037 — 4,037 4,037 — Non-U.S. sovereign securities (1) 389 389 89 300 U.S. reverse repurchase agreements 2,541 — 2,541 2,541 — Corporate debt securities (1) 2,544 (5) 2,539 2,544 Money market funds 1,516 — 1,516 1,516 — Time deposits (1) 928 — 928 928 — Subtotal 11,955 (5) 11,950 9,111 2,844 Unrealized Loss U.S. Gov't securities 21,930 (48) 21,882 2,189 19,693 Corporate debt securities 243 (1) 242 55 187 Subtotal available for sale debt (2) $ 22,173 (49) 22,124 2,244 19,880 Total cash, cash equivalents and current marketable securities $ 34,128 (54) 34,074 11,355 22,724 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. As of the fiscal year ended January 2, 2022 the carrying amount was approximately the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities as of October 2, 2022 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 22,153 22,104 Due after one year through five years 20 20 Due after five years through ten years — — Total debt securities $ 22,173 22,124 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October 2, 2022: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 4,424 4,422 Non-Current Debt 6.73% Debentures due 2023 250 256 3.375% Notes due 2023 802 797 0.650% Notes due 2024 (750MM Euro 0.9712) 722 702 5.50% Notes due 2024 (500MM GBP 1.0908) 544 548 2.625% Notes due 2025 749 721 0.550% Notes due 2025 922 826 2.45% Notes due 2026 1,996 1,868 2.95% Notes due 2027 877 829 0.95% Notes due 2027 1,396 1,185 2.90% Notes due 2028 1,496 1,379 1.150% Notes due 2028 (750MM Euro 0.9712) 724 649 6.95% Notes due 2029 298 342 1.30% Notes due 2030 1,606 1,276 4.95% Debentures due 2033 498 507 4.375% Notes due 2033 855 820 1.650% Notes due 2035 (1.5B Euro 0.9712) 1,450 1,181 3.55% Notes due 2036 841 726 5.95% Notes due 2037 993 1,074 3.625% Notes due 2037 1,334 1,154 3.40% Notes due 2038 992 822 5.85% Debentures due 2038 697 747 4.50% Debentures due 2040 540 506 2.10% Notes due 2040 827 551 4.85% Notes due 2041 297 291 4.50% Notes due 2043 496 457 3.70% Notes due 2046 1,976 1,626 3.75% Notes due 2047 811 668 3.50% Notes due 2048 743 593 2.25% Notes due 2050 809 500 2.45% Notes due 2060 1,054 619 Other 8 12 Total Non-Current Debt $ 27,603 24,232 The weighted average effective interest rate on non-current debt is 3.06%. The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022. The current debt balance as of October 2, 2022 includes $3.9 billion of commercial paper which has a weighted average interest rate of 2.88% and a weighted average maturity of approximately three months.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 02, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal nine months of 2022 and 2021 were 17.7% and 10.0%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal nine months is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations. Accordingly, the Company recorded a local deferred tax benefit of approximately $2.3 billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7 billion. The net impact of this reorganization was an approximate $0.6 billion net benefit or a 3.4% decrease to the effective tax rate of the fiscal nine months of 2021. Additionally, the following items had an unfavorable impact to the Company’s year-to-date effective tax rate as compared to the same period in the prior fiscal year: • as part of the planned separation of the Company’s Consumer Health business (for further information see Note 1 in the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022) the Company has recognized approximately $0.4 billion in net incremental tax costs which increased the rate by approximately 2.0% for the fiscal nine months of 2022 • certain one-time favorable tax items that occurred during the fiscal nine months of 2021 and resulted in an approximate 1.0% benefit to the effective tax rate, but were not repeated in fiscal 2022 • In the fiscal third quarter of 2021 the Company had accrued additional Talc expenses of $1.4 billion at an effective tax rate of 23.5% and $0.8 billion for the Risperdal Gynecomastia settlement at an effective tax rate of 16.4%. (See note 11 to the Consolidated Financial Statements for more details) • in the fiscal third quarter of 2021 the Company recorded a partial IPR&D charge of $0.9 billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4% The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during the first three fiscal quarters of 2022 and 2021. The Company’s 2022 tax rate benefited primarily from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD IPR&D (for further information see Note 3 of the Consolidated Financial Statements) and changes in the fair value of securities in the Company’s investment portfolio, both recorded at the U.S. statutory rate. As of October 2, 2022, the Company had approximately $3.8 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	9 Months Ended
	Oct. 02, 2022
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Service cost $ 313 339 80 78 953 1,019 240 232 Interest cost 226 192 26 20 685 578 79 61 Expected return on plan assets (683) (661) (2) (1) (2,075) (1,988) (6) (5) Amortization of prior service cost/(credit) (46) (46) (1) (8) (138) (136) (4) (23) Recognized actuarial losses 163 314 30 38 492 944 91 113 Curtailments and settlements — — — — 1 1 — — Net periodic benefit cost/(credit) $ (27) 138 133 127 (82) 418 400 378 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the fiscal nine months ended October 2, 2022, the Company contributed $82 million and $15 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Oct. 02, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 2, 2022 $ (10,017) (3) (2,702) (336) (13,058) Net change (1,957) (35) 344 (586) (2,234) October 2, 2022 $ (11,974) (38) (2,358) (922) (15,292) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Oct. 02, 2022
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Basic net earnings per share $ 1.70 1.39 5.49 6.13 Average shares outstanding — basic 2,627.9 2,632.6 2,628.9 2,632.2 Potential shares exercisable under stock option plans 140.1 138.3 141.1 139.1 Less: shares which could be repurchased under treasury stock method (106.7) (96.0) (102.5) (96.7) Average shares outstanding — diluted 2,661.3 2,674.9 2,667.5 2,674.6 Diluted net earnings per share $ 1.68 1.37 5.41 6.04 The diluted net earnings per share calculation for both the fiscal third quarter ended October 2, 2022 and October 3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company’s stock.

Segments of Business and Geogra

Segments of Business and Geographic Areas	9 Months Ended
	Oct. 02, 2022
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 2, October 3, Percent October 2, October 3, Percent Change CONSUMER HEALTH (1) OTC U.S. $ 695 686 1.4 % $ 2,028 1,960 3.5 % International 825 798 3.4 2,434 2,223 9.5 Worldwide 1,519 1,484 2.5 4,462 4,183 6.7 Skin Health/Beauty U.S. 591 569 3.7 1,764 1,862 (5.3) International 535 555 (3.6) 1,500 1,595 (6.0) Worldwide 1,126 1,124 0.1 3,264 3,457 (5.6) Oral Care U.S. 158 150 5.2 471 478 (1.5) International 217 248 (12.4) 664 762 (12.8) Worldwide 375 398 (5.8) 1,135 1,240 (8.5) Baby Care U.S. 91 95 (4.0) 264 288 (8.2) International 283 296 (4.5) 840 879 (4.4) Worldwide 375 391 (4.3) 1,105 1,167 (5.4) Women's Health U.S. 2 3 (22.0) 9 9 (2.8) International 222 229 (2.7) 674 675 (0.1) Worldwide 225 232 (3.0) 684 684 (0.1) Wound Care/Other U.S. 122 122 (0.2) 366 390 (6.0) International 53 61 (11.4) 170 186 (8.2) Worldwide 176 182 (3.9) 537 575 (6.7) TOTAL CONSUMER HEALTH U.S. 1,659 1,625 2.1 4,903 4,987 (1.7) International 2,136 2,187 (2.3) 6,283 6,320 (0.6) Worldwide 3,795 3,812 (0.4) 11,186 11,307 (1.1) PHARMACEUTICAL (1) Immunology U.S. 2,876 2,771 3.8 8,230 7,932 3.8 International 1,411 1,480 (4.7) 4,587 4,464 2.8 Worldwide 4,287 4,250 0.9 12,817 12,395 3.4 REMICADE U.S. 350 480 (27.0) 1,099 1,508 (27.1) U.S. Exports 39 47 (16.9) 163 197 (17.2) International 169 234 (27.8) 606 721 (16.0) Worldwide 558 761 (26.6) 1,868 2,426 (23.0) SIMPONI / SIMPONI ARIA U.S. 298 295 0.9 886 840 5.4 International 248 276 (10.4) 797 877 (9.2) Worldwide 545 571 (4.6) 1,682 1,717 (2.0) STELARA U.S. 1,655 1,569 5.5 4,766 4,396 8.4 International 794 809 (1.9) 2,571 2,404 6.9 Worldwide 2,449 2,378 3.0 7,336 6,800 7.9 TREMFYA U.S. 530 376 40.7 1,303 975 33.6 International 200 161 24.6 613 459 33.7 Worldwide 729 537 35.9 1,916 1,434 33.6 OTHER IMMUNOLOGY U.S. 5 3 * 14 15 (3.5) International 0 0 * 0 3 * Worldwide 5 3 * 14 18 (19.3) Infectious Diseases U.S. 390 679 (42.7) 1,266 1,635 (22.6) International 905 698 29.7 2,642 1,758 50.3 Worldwide 1,295 1,378 (6.0) 3,908 3,394 15.2 COVID-19 VACCINE U.S. 0 270 * 120 421 (71.5) International 489 233 * 1,370 346 * Worldwide 489 502 (2.7) 1,490 766 * EDURANT / rilpivirine U.S. 9 12 (27.1) 27 31 (14.5) International 237 247 (4.2) 691 733 (5.7) Worldwide 245 259 (5.2) 718 764 (6.1) PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 372 380 (2.2) 1,096 1,128 (2.9) International 112 137 (17.9) 354 440 (19.5) Worldwide 485 517 (6.4) 1,450 1,568 (7.5) OTHER INFECTIOUS DISEASES U.S. 10 18 (46.4) 24 55 (57.2) International 68 82 (17.1) 228 240 (5.0) Worldwide 77 99 (22.4) 251 295 (14.8) Neuroscience U.S. 919 835 10.0 2,658 2,448 8.6 International 763 845 (9.9) 2,498 2,751 (9.2) Worldwide 1,681 1,680 0.0 5,156 5,199 (0.8) CONCERTA / methylphenidate U.S. 41 35 19.3 114 117 (2.2) International 117 122 (4.4) 362 372 (2.6) Worldwide 158 157 0.8 476 489 (2.5) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 684 648 5.3 2,036 1,882 8.1 International 348 355 (2.3) 1,097 1,111 (1.3) Worldwide 1,031 1,004 2.6 3,132 2,994 4.6 RISPERDAL CONSTA U.S. 67 71 (6.1) 195 210 (7.1) International 52 69 (24.2) 178 242 (26.3) Worldwide 119 140 (14.9) 373 452 (17.4) OTHER NEUROSCIENCE U.S. 127 81 57.2 313 239 31.1 International 246 298 (17.9) 861 1,026 (16.2) Worldwide 374 379 (1.9) 1,174 1,265 (7.3) Oncology U.S. 1,812 1,525 18.8 5,073 4,364 16.2 International 2,252 2,140 5.2 6,983 6,406 9.0 Worldwide 4,064 3,665 10.9 12,056 10,770 11.9 DARZALEX U.S. 1,097 841 30.3 3,071 2,302 33.4 International 955 739 29.3 2,823 2,076 36.0 Worldwide 2,052 1,580 29.8 5,894 4,378 34.6 ERLEADA U.S. 254 214 19.1 693 578 20.0 International 235 130 * 647 329 * Worldwide 490 344 42.2 1,340 907 47.7 IMBRUVICA U.S. 353 413 (14.6) 1,072 1,311 (18.3) International 559 654 (14.6) 1,847 1,996 (7.5) Worldwide 911 1,066 (14.6) 2,918 3,307 (11.8) ZYTIGA / abiraterone acetate U.S. 16 25 (33.1) 54 96 (43.4) International 440 523 (15.9) 1,446 1,653 (12.5) Worldwide 456 548 (16.7) 1,500 1,749 (14.2) OTHER ONCOLOGY U.S. 92 32 * 183 76 * International 64 94 (32.1) 220 352 (37.5) Worldwide 155 126 23.1 403 428 (5.9) Pulmonary Hypertension U.S. 604 610 (1.1) 1,736 1,778 (2.4) International 247 258 (3.8) 810 821 (1.3) Worldwide 852 868 (1.9) 2,547 2,599 (2.0) OPSUMIT U.S. 289 299 (3.4) 827 861 (4.0) International 152 159 (4.7) 495 510 (3.0) Worldwide 441 458 (3.9) 1,322 1,371 (3.6) UPTRAVI U.S. 283 265 6.6 824 792 3.9 International 50 44 14.2 162 135 20.4 Worldwide 333 309 7.7 986 927 6.3 OTHER PULMONARY HYPERTENSION U.S. 33 47 (29.5) 86 125 (31.3) International 46 54 (15.7) 154 176 (13.0) Worldwide 78 101 (22.1) 239 301 (20.5) Cardiovascular / Metabolism / Other U.S. 837 800 4.5 2,266 2,379 (4.8) International 198 241 (17.5) 651 727 (10.4) Worldwide 1,034 1,041 (0.6) 2,916 3,106 (6.1) XARELTO U.S. 689 636 8.4 1,806 1,794 0.7 International — — — — — — Worldwide 689 636 8.4 1,806 1,794 0.7 INVOKANA / INVOKAMET U.S. 49 66 (25.8) 164 249 (34.1) International 60 67 (11.0) 193 194 (0.6) Worldwide 109 133 (18.4) 357 443 (19.5) OTHER (2) U.S. 98 98 (0.1) 295 336 (12.2) International 138 173 (20.0) 458 533 (14.0) Worldwide 236 271 (12.8) 753 869 (13.3) TOTAL PHARMACEUTICAL U.S. 7,438 7,221 3.0 21,229 20,536 3.4 International 5,776 5,661 2.0 18,171 16,927 7.3 Worldwide 13,214 12,882 2.6 39,400 37,463 5.2 MEDTECH (3) Interventional Solutions U.S. 547 444 23.2 1,566 1,353 15.7 International 513 513 0.0 1,636 1,599 2.3 Worldwide 1,060 957 10.8 3,202 2,952 8.5 Orthopaedics U.S. 1,309 1,249 4.8 3,936 3,821 3.0 International 785 843 (6.9) 2,504 2,611 (4.1) Worldwide 2,095 2,093 0.1 6,440 6,433 0.1 HIPS U.S. 228 209 9.1 693 651 6.5 International 124 146 (15.1) 437 451 (3.3) Worldwide 352 355 (0.9) 1,129 1,102 2.5 KNEES U.S. 203 184 9.8 620 579 6.9 International 115 131 (12.8) 386 403 (4.4) Worldwide 317 316 0.4 1,005 983 2.3 TRAUMA U.S. 473 455 3.8 1,412 1,352 4.4 International 244 260 (6.0) 749 805 (7.0) Worldwide 717 715 0.2 2,161 2,157 0.2 SPINE, SPORTS & OTHER U.S. 406 401 1.3 1,211 1,239 (2.2) International 303 306 (1.1) 933 952 (2.0) Worldwide 708 706 0.3 2,144 2,190 (2.1) Surgery U.S. 984 948 3.7 2,897 2,881 0.5 International 1,439 1,457 (1.2) 4,410 4,418 (0.2) Worldwide 2,422 2,405 0.7 7,306 7,299 0.1 ADVANCED U.S. 457 440 3.8 1,328 1,304 1.8 International 701 705 (0.4) 2,132 2,126 0.3 Worldwide 1,158 1,144 1.2 3,460 3,430 0.9 GENERAL U.S. 527 508 3.6 1,569 1,577 (0.5) International 737 752 (2.0) 2,277 2,292 (0.6) Worldwide 1,264 1,261 0.3 3,846 3,869 (0.6) Vision U.S. 517 475 8.8 1,534 1,414 8.5 International 689 714 (3.5) 2,170 2,103 3.2 Worldwide 1,206 1,189 1.4 3,704 3,517 5.3 CONTACT LENSES / OTHER U.S. 405 359 12.6 1,179 1,082 9.0 International 503 522 (3.6) 1,533 1,525 0.5 Worldwide 908 882 3.0 2,712 2,607 4.0 SURGICAL U.S. 112 117 (3.2) 355 333 6.8 International 186 191 (3.3) 637 577 10.3 Worldwide 298 308 (3.2) 992 910 9.0 TOTAL MEDTECH U.S. 3,356 3,117 7.7 9,932 9,470 4.9 International 3,426 3,527 (2.9) 10,719 10,731 (0.1) Worldwide 6,782 6,644 2.1 20,651 20,201 2.2 WORLDWIDE U.S. 12,453 11,963 4.1 36,064 34,993 3.1 International 11,338 11,375 (0.3) 35,173 33,978 3.5 Worldwide $ 23,791 23,338 1.9 % $ 71,237 68,971 3.3 % *Percentage greater than 100% or not meaningful (1) Approximately $0.1 billion in the fiscal third quarter of 2021 and $0.3 billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Previously referred to as Medical Devices EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT* Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 2, October 3, Percent October 2, October 3, Percent Consumer Health (1) $ 809 (577) ** $ 2,279 1,131 ** Pharmaceutical (2) 4,249 4,200 1.2 12,593 13,663 (7.8) MedTech (3) 1,124 423 ** 3,742 3,798 (1.5) Segment earnings before provision for taxes 6,182 4,046 52.8 18,614 18,592 0.1 Less: Expense not allocated to segments (4) 111 197 471 652 Less: Consumer Health separation costs 249 — 619 — Worldwide income before tax $ 5,822 3,849 51.3 % $ 17,524 17,940 (2.3) % *The 2021 fiscal third quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes **Percentage greater than 100% or not meaningful (1) Consumer Health includes: • Intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.3 billion in both the fiscal nine months of 2022 and 2021. • Litigation expense of $0.1 billion in the fiscal nine months of 2022. Litigation expense of $1.4 billion and $1.5 billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs. (2) Pharmaceutical includes: • Divestiture gains of $0.6 billion in the fiscal nine months of 2021 related to two brands outside the U.S. • Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $2.2 billion and $2.5 billion in the fiscal nine months of 2022 and 2021, respectively. • In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. • A loss of $0.2 billion and a gain of $0.1 billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $0.7 billion and a gain of $0.2 billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively. • COVID-19 Vaccine supply network related costs of $0.4 billion and $0.7 billion in the fiscal third quarter and fiscal nine months 2022, respectively. • Litigation expense of $0.8 billion and $0.7 billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia. In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5 billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) MedTech includes: • Litigation expense of $0.2 billion in the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs. • A restructuring related charge of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.2 billion in the fiscal nine months of 2022 and 2021, respectively. • Intangible amortization expense of $0.3 billion in both the fiscal third quarter of 2022 and 2021 and $0.8 billion in both the fiscal nine months of 2022 and 2021. • Includes an in-process research and development expense of $0.9 billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 2, 2022 October 3, 2021 Percent October 2, 2022 October 3, 2021 Percent Change United States $ 12,453 11,963 4.1 % $ 36,064 34,993 3.1 % Europe 5,524 5,587 (1.1) 17,633 16,669 5.8 Western Hemisphere, excluding U.S. 1,562 1,500 4.1 4,580 4,291 6.7 Asia-Pacific, Africa 4,252 4,288 (0.9) 12,960 13,018 (0.4) Total $ 23,791 23,338 1.9 % $ 71,237 68,971 3.3 %

Acquisitions and Divestitures

Acquisitions and Divestitures	9 Months Ended
	Oct. 02, 2022
Business Combinations [Abstract]
Acquisitions and Divestitures	ACQUISITIONS AND DIVESTITURESThere were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6 billion.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Oct. 02, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON’S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of October 2, 2022, in the United States there were approximately 180 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,400 with respect to the PINNACLE Acetabular Cup System; 9,400 with respect to pelvic meshes; 1,500 with respect to RISPERDAL; 600 with respect to XARELTO; 40,300 with respect to body powders containing talc; 5 with respect to INVOKANA; 4,800 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and 1,900 with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. In September 2022, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of October 2022, there are approximately 154 active cases subject to these orders which are being reviewed and evaluated. Claims have also been filed against Ethicon and Johnson & Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Ethicon and Johnson & Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company’s accruals. Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson; and JPI’s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson & Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation. A significant number of personal injury claims alleging that talc causes cancer were made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities). In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson & Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. While the New Jersey Bankruptcy Court’s order effectively stays all of the Company’s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed. The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2 billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2 billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued. A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that J&J fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by Johnson & Johnson’s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants’ Committee (TCC), and the Future Claimants’ Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent’s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys’s insurers (the Mediation Parties) agreed to engage in mediation. The term of the mediation ended in September 2022. In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company’s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding. In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing “talc-related claims” against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023. In February 2021, several of the Company’s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff’s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff’s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record. In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court’s order. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson & Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation . In July 2020, a report was delivered to the Company’s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th e In re Johnson & Johnson Talc Stockholder Derivative Litigation . The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel’s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson & Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson & Johnson’s motion to dismiss pending a decision on Plaintiff’s motion for discovery. In July 2022, the Court denied Plaintiff’s discovery motion. In August 2022, the Court reopened Johnson & Johnson’s motion to dismiss. In lieu of opposing, Plaintiff made a motion to voluntarily dismiss the case, which the Court granted in October 2022. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants’ motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants’ motion was complete. In February 2021, the Court granted Defendants’ motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July

Restructuring

Restructuring	9 Months Ended
	Oct. 02, 2022
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal third quarter of 2022, the Company recorded a net pre-tax charge of $123 million, which is included on the following lines of the Consolidated Statement of Earnings, $82 million in restructuring, $13 million in cost of products sold and $28 million in other (income) expense, net. In the fiscal nine months of 2022, the Company recorded a net pre-tax charge of $323 million, which is included on the following lines of the Consolidated Statement of Earnings, $237 million in restructuring, $46 million in cost of products sold and $40 million in other (income) expense, net. Total project costs of approximately $2.1 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.7 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.2 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2022: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, January 2, 2022 $ 112 — 25 137 Current year activity: Charges — (4) 327 323 Cash settlements (28) 35 (3) (317) (310) Settled non cash — (31) — (31) Reserve balance, October 2, 2022 (1) $ 84 — 35 119 (1) Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Represents gain on sale of assets The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 02, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended October 2, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
New and Recently Adopted Accounting Standards	New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. Recently Adopted Accounting Standards There were no new material accounting standards adopted in the fiscal third quarter of 2022. Recently Issued Accounting Standards Not Adopted as of October 2, 2022 ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) – Disclosure of Supplier Finance Program Obligations This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity’s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.
Cash and Cash Equivalents	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 02, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) October 2, 2022 January 2, 2022 Raw materials and supplies $ 1,730 1,592 Goods in process 2,106 2,287 Finished goods 7,839 6,508 Total inventories $ 11,675 10,387

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Oct. 02, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) October 2, 2022 January 2, 2022 Intangible assets with definite lives: Patents and trademarks — gross (1) $ 35,132 38,572 Less accumulated amortization (20,116) (20,088) Patents and trademarks — net 15,016 18,484 Customer relationships and other intangibles — gross 22,302 23,011 Less accumulated amortization (12,406) (11,925) Customer relationships and other intangibles — net (2) 9,896 11,086 Intangible assets with indefinite lives: Trademarks 6,648 6,985 Purchased in-process research and development (3) 8,776 9,837 Total intangible assets with indefinite lives 15,424 16,822 Total intangible assets — net $ 40,336 46,392 (1) The change in intangible assets with definite lives is primarily the result of currency translation effects. (2) The majority is comprised of customer relationships (3) In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives. In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2 billion in the fiscal fourth quarter related to this impairment. The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.
Goodwill	Goodwill as of October 2, 2022 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical MedTech Total Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246 Goodwill, related to acquisitions — — 195 195 Currency translation/Other (1,037) (920) (101) (2,058) Goodwill at October 2, 2022 $ 8,773 9,660 14,950 33,383
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2022 2023 2024 2025 2026 $4,300 4,300 4,100 3,400 2,800

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 02, 2022
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2022 and 2021, net of tax: October 2, 2022 October 3, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (322) — — — — (62) — Derivatives designated as hedging instruments — — — 322 — — — — 62 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 13 — — — — 34 — Amount of gain or (loss) recognized in AOCI — — — 13 — — — — 34 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (20) (83) 53 — 22 (3) 58 8 — 19 Amount of gain or (loss) recognized in AOCI (45) (94) 91 — 36 (35) (155) 37 — 42 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 120 — — — 117 — Amount of gain or (loss) recognized in AOCI $ — — — (205) — — — — 144 — The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2022 and 2021, net of tax: October 2, 2022 October 3, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (1,094) — — — — (56) — Derivatives designated as hedging instruments — — — 1,094 — — — — 56 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 102 — — — — 115 — Amount of gain or (loss) recognized in AOCI — — — 102 — — — — 115 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (54) (141) 118 — (35) 25 106 (1) — 24 Amount of gain or (loss) recognized in AOCI (48) (153) 193 — (75) (41) (398) 80 — 67 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 342 — — — — 307 — Amount of gain or (loss) recognized in AOCI $ — — — (273) — — — — 122 — The following table is the effect of net investment hedges for the fiscal third quarters ended in 2022 and 2021: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Debt $ 208 115 Interest (income) expense — — Cross Currency interest rate swaps $ 261 141 Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal nine months ended in 2022 and 2021 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Debt $ 478 279 Interest (income) expense — — Cross Currency interest rate swaps $ 1,134 432 Interest (income) expense — —
Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet	As of October 2, 2022, and January 2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) October 2, 2022 January 2, 2022 October 2, 2022 January 2, 2022 Long-term Debt $ 8,668 9,793 (1,430) (142)
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2022 and 2021: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Foreign Exchange Contracts Other (income) expense $ 109 (13) 211 (50)
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: (Dollars in Millions) January 2, 2022 October 2, 2022 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,884 (607) (755) 522 522 Equity Investments without readily determinable value $ 500 (29) 60 531 531 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of October 2, 2022 and January 2, 2022 were as follows: October 2, 2022 January 2, 2022 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 1,942 — 1,942 540 Interest rate contracts (2) — 2,533 — 2,533 796 Total — 4,475 — 4,475 1,336 Liabilities: Forward foreign exchange contracts — 1,881 — 1,881 881 Interest rate contracts (2) — 1,884 — 1,884 979 Total — 3,765 — 3,765 1,860 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 178 — 178 24 Liabilities: Forward foreign exchange contracts — 68 — 68 28 Other Investments: Equity investments (3) 522 — — 522 1,884 Debt securities (4) — 22,124 — 22,124 19,727 Other Liabilities Contingent consideration (5) $ — — 525 525 533 Gross to Net Derivative Reconciliation October 2, 2022 January 2, 2022 (Dollars in Millions) Total Gross Assets $ 4,653 1,360 Credit Support Agreement (CSA) (4,440) (1,285) Total Net Asset 213 75 Total Gross Liabilities 3,833 1,888 Credit Support Agreement (CSA) (3,636) (1,855) Total Net Liabilities $ 197 33 Summarized information about changes in liabilities for contingent consideration for each of the fiscal nine months ended is as follows: October 2, 2022 October 3, 2021 (Dollars in Millions) Beginning Balance $ 533 $ 633 Changes in estimated fair value (6) (85) 28 Additions 89 — Payments (12) (48) Ending Balance $ 525 $ 613 (1) 2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Includes $507 million and $520 million, classified as non-current other liabilities as of October 2, 2022 and January 2, 2022, respectively. Includes $18 million and $13 million classified as current liabilities as of October 2, 2022 and January 2, 2022, respectively.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of October 2, 2022 comprised: (Dollars in Millions) Carrying Amount Gain/( Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 4,037 — 4,037 4,037 — Non-U.S. sovereign securities (1) 389 389 89 300 U.S. reverse repurchase agreements 2,541 — 2,541 2,541 — Corporate debt securities (1) 2,544 (5) 2,539 2,544 Money market funds 1,516 — 1,516 1,516 — Time deposits (1) 928 — 928 928 — Subtotal 11,955 (5) 11,950 9,111 2,844 Unrealized Loss U.S. Gov't securities 21,930 (48) 21,882 2,189 19,693 Corporate debt securities 243 (1) 242 55 187 Subtotal available for sale debt (2) $ 22,173 (49) 22,124 2,244 19,880 Total cash, cash equivalents and current marketable securities $ 34,128 (54) 34,074 11,355 22,724 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of October 2, 2022 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 22,153 22,104 Due after one year through five years 20 20 Due after five years through ten years — — Total debt securities $ 22,173 22,124
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October 2, 2022: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 4,424 4,422 Non-Current Debt 6.73% Debentures due 2023 250 256 3.375% Notes due 2023 802 797 0.650% Notes due 2024 (750MM Euro 0.9712) 722 702 5.50% Notes due 2024 (500MM GBP 1.0908) 544 548 2.625% Notes due 2025 749 721 0.550% Notes due 2025 922 826 2.45% Notes due 2026 1,996 1,868 2.95% Notes due 2027 877 829 0.95% Notes due 2027 1,396 1,185 2.90% Notes due 2028 1,496 1,379 1.150% Notes due 2028 (750MM Euro 0.9712) 724 649 6.95% Notes due 2029 298 342 1.30% Notes due 2030 1,606 1,276 4.95% Debentures due 2033 498 507 4.375% Notes due 2033 855 820 1.650% Notes due 2035 (1.5B Euro 0.9712) 1,450 1,181 3.55% Notes due 2036 841 726 5.95% Notes due 2037 993 1,074 3.625% Notes due 2037 1,334 1,154 3.40% Notes due 2038 992 822 5.85% Debentures due 2038 697 747 4.50% Debentures due 2040 540 506 2.10% Notes due 2040 827 551 4.85% Notes due 2041 297 291 4.50% Notes due 2043 496 457 3.70% Notes due 2046 1,976 1,626 3.75% Notes due 2047 811 668 3.50% Notes due 2048 743 593 2.25% Notes due 2050 809 500 2.45% Notes due 2060 1,054 619 Other 8 12 Total Non-Current Debt $ 27,603 24,232

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	9 Months Ended
	Oct. 02, 2022
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Service cost $ 313 339 80 78 953 1,019 240 232 Interest cost 226 192 26 20 685 578 79 61 Expected return on plan assets (683) (661) (2) (1) (2,075) (1,988) (6) (5) Amortization of prior service cost/(credit) (46) (46) (1) (8) (138) (136) (4) (23) Recognized actuarial losses 163 314 30 38 492 944 91 113 Curtailments and settlements — — — — 1 1 — — Net periodic benefit cost/(credit) $ (27) 138 133 127 (82) 418 400 378

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Oct. 02, 2022
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 2, 2022 $ (10,017) (3) (2,702) (336) (13,058) Net change (1,957) (35) 344 (586) (2,234) October 2, 2022 $ (11,974) (38) (2,358) (922) (15,292)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Oct. 02, 2022
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) October 2, 2022 October 3, 2021 October 2, 2022 October 3, 2021 Basic net earnings per share $ 1.70 1.39 5.49 6.13 Average shares outstanding — basic 2,627.9 2,632.6 2,628.9 2,632.2 Potential shares exercisable under stock option plans 140.1 138.3 141.1 139.1 Less: shares which could be repurchased under treasury stock method (106.7) (96.0) (102.5) (96.7) Average shares outstanding — diluted 2,661.3 2,674.9 2,667.5 2,674.6 Diluted net earnings per share $ 1.68 1.37 5.41 6.04

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	9 Months Ended
	Oct. 02, 2022
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 2, October 3, Percent October 2, October 3, Percent Change CONSUMER HEALTH (1) OTC U.S. $ 695 686 1.4 % $ 2,028 1,960 3.5 % International 825 798 3.4 2,434 2,223 9.5 Worldwide 1,519 1,484 2.5 4,462 4,183 6.7 Skin Health/Beauty U.S. 591 569 3.7 1,764 1,862 (5.3) International 535 555 (3.6) 1,500 1,595 (6.0) Worldwide 1,126 1,124 0.1 3,264 3,457 (5.6) Oral Care U.S. 158 150 5.2 471 478 (1.5) International 217 248 (12.4) 664 762 (12.8) Worldwide 375 398 (5.8) 1,135 1,240 (8.5) Baby Care U.S. 91 95 (4.0) 264 288 (8.2) International 283 296 (4.5) 840 879 (4.4) Worldwide 375 391 (4.3) 1,105 1,167 (5.4) Women's Health U.S. 2 3 (22.0) 9 9 (2.8) International 222 229 (2.7) 674 675 (0.1) Worldwide 225 232 (3.0) 684 684 (0.1) Wound Care/Other U.S. 122 122 (0.2) 366 390 (6.0) International 53 61 (11.4) 170 186 (8.2) Worldwide 176 182 (3.9) 537 575 (6.7) TOTAL CONSUMER HEALTH U.S. 1,659 1,625 2.1 4,903 4,987 (1.7) International 2,136 2,187 (2.3) 6,283 6,320 (0.6) Worldwide 3,795 3,812 (0.4) 11,186 11,307 (1.1) PHARMACEUTICAL (1) Immunology U.S. 2,876 2,771 3.8 8,230 7,932 3.8 International 1,411 1,480 (4.7) 4,587 4,464 2.8 Worldwide 4,287 4,250 0.9 12,817 12,395 3.4 REMICADE U.S. 350 480 (27.0) 1,099 1,508 (27.1) U.S. Exports 39 47 (16.9) 163 197 (17.2) International 169 234 (27.8) 606 721 (16.0) Worldwide 558 761 (26.6) 1,868 2,426 (23.0) SIMPONI / SIMPONI ARIA U.S. 298 295 0.9 886 840 5.4 International 248 276 (10.4) 797 877 (9.2) Worldwide 545 571 (4.6) 1,682 1,717 (2.0) STELARA U.S. 1,655 1,569 5.5 4,766 4,396 8.4 International 794 809 (1.9) 2,571 2,404 6.9 Worldwide 2,449 2,378 3.0 7,336 6,800 7.9 TREMFYA U.S. 530 376 40.7 1,303 975 33.6 International 200 161 24.6 613 459 33.7 Worldwide 729 537 35.9 1,916 1,434 33.6 OTHER IMMUNOLOGY U.S. 5 3 * 14 15 (3.5) International 0 0 * 0 3 * Worldwide 5 3 * 14 18 (19.3) Infectious Diseases U.S. 390 679 (42.7) 1,266 1,635 (22.6) International 905 698 29.7 2,642 1,758 50.3 Worldwide 1,295 1,378 (6.0) 3,908 3,394 15.2 COVID-19 VACCINE U.S. 0 270 * 120 421 (71.5) International 489 233 * 1,370 346 * Worldwide 489 502 (2.7) 1,490 766 * EDURANT / rilpivirine U.S. 9 12 (27.1) 27 31 (14.5) International 237 247 (4.2) 691 733 (5.7) Worldwide 245 259 (5.2) 718 764 (6.1) PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 372 380 (2.2) 1,096 1,128 (2.9) International 112 137 (17.9) 354 440 (19.5) Worldwide 485 517 (6.4) 1,450 1,568 (7.5) OTHER INFECTIOUS DISEASES U.S. 10 18 (46.4) 24 55 (57.2) International 68 82 (17.1) 228 240 (5.0) Worldwide 77 99 (22.4) 251 295 (14.8) Neuroscience U.S. 919 835 10.0 2,658 2,448 8.6 International 763 845 (9.9) 2,498 2,751 (9.2) Worldwide 1,681 1,680 0.0 5,156 5,199 (0.8) CONCERTA / methylphenidate U.S. 41 35 19.3 114 117 (2.2) International 117 122 (4.4) 362 372 (2.6) Worldwide 158 157 0.8 476 489 (2.5) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 684 648 5.3 2,036 1,882 8.1 International 348 355 (2.3) 1,097 1,111 (1.3) Worldwide 1,031 1,004 2.6 3,132 2,994 4.6 RISPERDAL CONSTA U.S. 67 71 (6.1) 195 210 (7.1) International 52 69 (24.2) 178 242 (26.3) Worldwide 119 140 (14.9) 373 452 (17.4) OTHER NEUROSCIENCE U.S. 127 81 57.2 313 239 31.1 International 246 298 (17.9) 861 1,026 (16.2) Worldwide 374 379 (1.9) 1,174 1,265 (7.3) Oncology U.S. 1,812 1,525 18.8 5,073 4,364 16.2 International 2,252 2,140 5.2 6,983 6,406 9.0 Worldwide 4,064 3,665 10.9 12,056 10,770 11.9 DARZALEX U.S. 1,097 841 30.3 3,071 2,302 33.4 International 955 739 29.3 2,823 2,076 36.0 Worldwide 2,052 1,580 29.8 5,894 4,378 34.6 ERLEADA U.S. 254 214 19.1 693 578 20.0 International 235 130 * 647 329 * Worldwide 490 344 42.2 1,340 907 47.7 IMBRUVICA U.S. 353 413 (14.6) 1,072 1,311 (18.3) International 559 654 (14.6) 1,847 1,996 (7.5) Worldwide 911 1,066 (14.6) 2,918 3,307 (11.8) ZYTIGA / abiraterone acetate U.S. 16 25 (33.1) 54 96 (43.4) International 440 523 (15.9) 1,446 1,653 (12.5) Worldwide 456 548 (16.7) 1,500 1,749 (14.2) OTHER ONCOLOGY U.S. 92 32 * 183 76 * International 64 94 (32.1) 220 352 (37.5) Worldwide 155 126 23.1 403 428 (5.9) Pulmonary Hypertension U.S. 604 610 (1.1) 1,736 1,778 (2.4) International 247 258 (3.8) 810 821 (1.3) Worldwide 852 868 (1.9) 2,547 2,599 (2.0) OPSUMIT U.S. 289 299 (3.4) 827 861 (4.0) International 152 159 (4.7) 495 510 (3.0) Worldwide 441 458 (3.9) 1,322 1,371 (3.6) UPTRAVI U.S. 283 265 6.6 824 792 3.9 International 50 44 14.2 162 135 20.4 Worldwide 333 309 7.7 986 927 6.3 OTHER PULMONARY HYPERTENSION U.S. 33 47 (29.5) 86 125 (31.3) International 46 54 (15.7) 154 176 (13.0) Worldwide 78 101 (22.1) 239 301 (20.5) Cardiovascular / Metabolism / Other U.S. 837 800 4.5 2,266 2,379 (4.8) International 198 241 (17.5) 651 727 (10.4) Worldwide 1,034 1,041 (0.6) 2,916 3,106 (6.1) XARELTO U.S. 689 636 8.4 1,806 1,794 0.7 International — — — — — — Worldwide 689 636 8.4 1,806 1,794 0.7 INVOKANA / INVOKAMET U.S. 49 66 (25.8) 164 249 (34.1) International 60 67 (11.0) 193 194 (0.6) Worldwide 109 133 (18.4) 357 443 (19.5) OTHER (2) U.S. 98 98 (0.1) 295 336 (12.2) International 138 173 (20.0) 458 533 (14.0) Worldwide 236 271 (12.8) 753 869 (13.3) TOTAL PHARMACEUTICAL U.S. 7,438 7,221 3.0 21,229 20,536 3.4 International 5,776 5,661 2.0 18,171 16,927 7.3 Worldwide 13,214 12,882 2.6 39,400 37,463 5.2 MEDTECH (3) Interventional Solutions U.S. 547 444 23.2 1,566 1,353 15.7 International 513 513 0.0 1,636 1,599 2.3 Worldwide 1,060 957 10.8 3,202 2,952 8.5 Orthopaedics U.S. 1,309 1,249 4.8 3,936 3,821 3.0 International 785 843 (6.9) 2,504 2,611 (4.1) Worldwide 2,095 2,093 0.1 6,440 6,433 0.1 HIPS U.S. 228 209 9.1 693 651 6.5 International 124 146 (15.1) 437 451 (3.3) Worldwide 352 355 (0.9) 1,129 1,102 2.5 KNEES U.S. 203 184 9.8 620 579 6.9 International 115 131 (12.8) 386 403 (4.4) Worldwide 317 316 0.4 1,005 983 2.3 TRAUMA U.S. 473 455 3.8 1,412 1,352 4.4 International 244 260 (6.0) 749 805 (7.0) Worldwide 717 715 0.2 2,161 2,157 0.2 SPINE, SPORTS & OTHER U.S. 406 401 1.3 1,211 1,239 (2.2) International 303 306 (1.1) 933 952 (2.0) Worldwide 708 706 0.3 2,144 2,190 (2.1) Surgery U.S. 984 948 3.7 2,897 2,881 0.5 International 1,439 1,457 (1.2) 4,410 4,418 (0.2) Worldwide 2,422 2,405 0.7 7,306 7,299 0.1 ADVANCED U.S. 457 440 3.8 1,328 1,304 1.8 International 701 705 (0.4) 2,132 2,126 0.3 Worldwide 1,158 1,144 1.2 3,460 3,430 0.9 GENERAL U.S. 527 508 3.6 1,569 1,577 (0.5) International 737 752 (2.0) 2,277 2,292 (0.6) Worldwide 1,264 1,261 0.3 3,846 3,869 (0.6) Vision U.S. 517 475 8.8 1,534 1,414 8.5 International 689 714 (3.5) 2,170 2,103 3.2 Worldwide 1,206 1,189 1.4 3,704 3,517 5.3 CONTACT LENSES / OTHER U.S. 405 359 12.6 1,179 1,082 9.0 International 503 522 (3.6) 1,533 1,525 0.5 Worldwide 908 882 3.0 2,712 2,607 4.0 SURGICAL U.S. 112 117 (3.2) 355 333 6.8 International 186 191 (3.3) 637 577 10.3 Worldwide 298 308 (3.2) 992 910 9.0 TOTAL MEDTECH U.S. 3,356 3,117 7.7 9,932 9,470 4.9 International 3,426 3,527 (2.9) 10,719 10,731 (0.1) Worldwide 6,782 6,644 2.1 20,651 20,201 2.2 WORLDWIDE U.S. 12,453 11,963 4.1 36,064 34,993 3.1 International 11,338 11,375 (0.3) 35,173 33,978 3.5 Worldwide $ 23,791 23,338 1.9 % $ 71,237 68,971 3.3 % *Percentage greater than 100% or not meaningful (1) Approximately $0.1 billion in the fiscal third quarter of 2021 and $0.3 billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Previously referred to as Medical Devices
Operating Profit by Segment of Business	EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT* Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 2, October 3, Percent October 2, October 3, Percent Consumer Health (1) $ 809 (577) ** $ 2,279 1,131 ** Pharmaceutical (2) 4,249 4,200 1.2 12,593 13,663 (7.8) MedTech (3) 1,124 423 ** 3,742 3,798 (1.5) Segment earnings before provision for taxes 6,182 4,046 52.8 18,614 18,592 0.1 Less: Expense not allocated to segments (4) 111 197 471 652 Less: Consumer Health separation costs 249 — 619 — Worldwide income before tax $ 5,822 3,849 51.3 % $ 17,524 17,940 (2.3) % *The 2021 fiscal third quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes **Percentage greater than 100% or not meaningful (1) Consumer Health includes: • Intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.3 billion in both the fiscal nine months of 2022 and 2021. • Litigation expense of $0.1 billion in the fiscal nine months of 2022. Litigation expense of $1.4 billion and $1.5 billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs. (2) Pharmaceutical includes: • Divestiture gains of $0.6 billion in the fiscal nine months of 2021 related to two brands outside the U.S. • Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $2.2 billion and $2.5 billion in the fiscal nine months of 2022 and 2021, respectively. • In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. • A loss of $0.2 billion and a gain of $0.1 billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $0.7 billion and a gain of $0.2 billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively. • COVID-19 Vaccine supply network related costs of $0.4 billion and $0.7 billion in the fiscal third quarter and fiscal nine months 2022, respectively. • Litigation expense of $0.8 billion and $0.7 billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia. In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5 billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) MedTech includes: • Litigation expense of $0.2 billion in the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs. • A restructuring related charge of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.2 billion in the fiscal nine months of 2022 and 2021, respectively. • Intangible amortization expense of $0.3 billion in both the fiscal third quarter of 2022 and 2021 and $0.8 billion in both the fiscal nine months of 2022 and 2021. • Includes an in-process research and development expense of $0.9 billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 2, 2022 October 3, 2021 Percent October 2, 2022 October 3, 2021 Percent Change United States $ 12,453 11,963 4.1 % $ 36,064 34,993 3.1 % Europe 5,524 5,587 (1.1) 17,633 16,669 5.8 Western Hemisphere, excluding U.S. 1,562 1,500 4.1 4,580 4,291 6.7 Asia-Pacific, Africa 4,252 4,288 (0.9) 12,960 13,018 (0.4) Total $ 23,791 23,338 1.9 % $ 71,237 68,971 3.3 %

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Oct. 02, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2022: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, January 2, 2022 $ 112 — 25 137 Current year activity: Charges — (4) 327 323 Cash settlements (28) 35 (3) (317) (310) Settled non cash — (31) — (31) Reserve balance, October 2, 2022 (1) $ 84 — 35 119 (1) Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Represents gain on sale of assets

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Oct. 02, 2022	Jan. 02, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 1,730	$ 1,592
Goods in process	2,106	2,287
Finished goods	7,839	6,508
Total inventories	$ 11,675	$ 10,387

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Oct. 27, 2022	Oct. 02, 2022	Jan. 02, 2022
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets		$ 15,424	$ 16,822
Total intangible assets - net		40,336	46,392
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets		6,648	6,985
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets		8,776	9,837
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross		35,132	38,572
Less accumulated amortization		(20,116)	(20,088)
Finite-Lived Intangible Assets, Net		15,016	18,484
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross		22,302	23,011
Less accumulated amortization		(12,406)	(11,925)
Finite-Lived Intangible Assets, Net		9,896	$ 11,086
In-process research and development | bermekimab
Intangible assets with indefinite lives:
Impairment of intangible assets		$ 600
In-process research and development | bermekimab | Subsequent Event
Intangible assets with indefinite lives:
Impairment of intangible assets	$ 200

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	9 Months Ended
	Oct. 02, 2022 USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 35,246
Goodwill, related to acquisitions	195
Currency translation/Other	(2,058)
Goodwill End of Period	33,383
CONSUMER HEALTH (1)
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,810
Goodwill, related to acquisitions	0
Currency translation/Other	(1,037)
Goodwill End of Period	8,773
PHARMACEUTICAL(1)
Goodwill [Roll Forward]
Goodwill Beginning of Period	10,580
Goodwill, related to acquisitions	0
Currency translation/Other	(920)
Goodwill End of Period	9,660
MedTech
Goodwill [Roll Forward]
Goodwill Beginning of Period	14,856
Goodwill, related to acquisitions	195
Currency translation/Other	(101)
Goodwill End of Period	$ 14,950

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Billions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization expense of amortizable intangible assets	$ 1	$ 1.1	$ 3.2	$ 3.6
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life			12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life			21 years

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) $ in Millions	Oct. 02, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 4,300
2023	4,300
2024	4,100
2025	3,400
2026	$ 2,800

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	6 Months Ended	9 Months Ended
	Jul. 03, 2022	Oct. 02, 2022	Jan. 02, 2022
Derivative [Line Items]
Accumulated other comprehensive income on derivatives, after tax		$ (922)
Reclassification of foreign exchange contracts into earnings, period		next 12 months
Maximum length of time for hedge exposure		18 months
Weighted average interest rate on non-current debt		3.06%
Excess of the estimated fair value over the carrying value of debt	$ 3,200
Current Debt		$ 4,424	$ 3,766
Commercial Paper
Derivative [Line Items]
Current Debt		$ 3,900
Weighted average interest rate		2.88%
Term		3 months
Forward foreign exchange contracts
Derivative [Line Items]
Collateral already posted, aggregate fair value		$ 800
Derivative, notional amount		47,100	45,800
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount		36,200	37,400
Interest Rate Swap
Derivative [Line Items]
Derivative, notional amount		10,000	$ 10,000
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Equity, fair value adjustment, impairment loss		(29)
Changes in Fair Value Reflected in Net Income		$ (29)

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0	$ 0	$ 0
Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			102	115
Amount of gain or (loss) recognized in AOCI			102	115
Fair Value Hedging | Interest Rate Swap | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	(322)	(62)	(1,094)	(56)
Amount of gain or (loss) recognized in AOCI	322	62	1,094	56
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	13	34
Amount of gain or (loss) recognized in AOCI	13	34
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(45)	(35)	(48)	(41)
Amount of gain or (loss) reclassified from AOCI into income	(20)	(3)	(54)	25
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(94)	(155)	(153)	(398)
Amount of gain or (loss) reclassified from AOCI into income	(83)	58	(141)	106
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	91	37	193	80
Amount of gain or (loss) reclassified from AOCI into income	53	8	118	(1)
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	36	42	(75)	67
Amount of gain or (loss) reclassified from AOCI into income	22	19	(35)	24
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0		0	0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(205)	144	(273)	122
Amount of gain or (loss) reclassified from AOCI into income	$ 120	$ 117	$ 342	$ 307

Fair Value Measurements - Deriv

Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($) $ in Millions	Oct. 02, 2022	Jan. 02, 2022
Derivative [Line Items]
Carrying Amount of the Hedged Liability	$ 3,833	$ 1,888
Long-term Debt | Designated as Hedging Instrument
Derivative [Line Items]
Carrying Amount of the Hedged Liability	8,668	9,793
Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability	$ (1,430)	$ (142)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Not Designated as Hedging Instrument | Forward foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ 109	$ (13)	$ 211	$ (50)

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	$ 208	$ 115	$ 478	$ 279
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	261	141	1,134	432
Cross Currency Interest Rate Contract | Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2022	Jan. 02, 2022
Equity Investment [Roll Forward]
Non Current Other Assets	$ 8,625	$ 10,216
Equity Securities
Equity Investment [Roll Forward]
Carrying value, end of period	600
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	1,884
Changes in Fair Value Reflected in Net Income	(607)
Sales/ Purchases/Other	(755)
Carrying value, end of period	522
Non Current Other Assets	522
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	500
Changes in Fair Value Reflected in Net Income	(29)
Sales/ Purchases/Other	60
Carrying value, end of period	531
Non Current Other Assets	$ 531

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Jan. 02, 2022
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 4,475
Derivatives designated as hedging instruments : Liabilities	3,765
Available-for-sale Securities, Equity Securities	522		$ 1,884
Available-for-sale Securities	22,124		19,727
Contingent consideration	525		533
Total Gross Assets	4,653		1,360
Credit Support Agreement (CSA)	(4,440)		(1,285)
Total Net Asset	213		75
Total Gross Liabilities	3,833		1,888
Credit Support Agreement (CSA)	(3,636)		(1,855)
Total Net Liabilities	197		33
Beginning Balance	533	$ 633
Changes in estimated fair value (6)	(85)	28
Additions	89	0
Payments	(12)	(48)
Ending Balance	525	$ 613
Equity Securities
Financial assets and liabilities at fair value
Marketable Securities, Noncurrent	600
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	522		1,884
Available-for-sale Securities	0
Contingent consideration	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	4,475		1,336
Derivatives designated as hedging instruments : Liabilities	3,765		1,860
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	22,124
Contingent consideration	0
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Contingent consideration	525		533
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	2,533
Derivatives designated as hedging instruments : Liabilities	1,884
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	2,533		796
Derivatives designated as hedging instruments : Liabilities	1,884		979
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,942
Derivatives designated as hedging instruments : Liabilities	1,881
Derivatives not designated as hedging instruments : Assets	178
Derivatives not designated as hedging instruments : Liabilities	68
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,942		540
Derivatives designated as hedging instruments : Liabilities	1,881		881
Derivatives not designated as hedging instruments : Assets	178		24
Derivatives not designated as hedging instruments : Liabilities	68		28
Forward foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Other Noncurrent Liabilities | Auris Health
Financial assets and liabilities at fair value
Contingent consideration	507		520
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration	$ 18		$ 13

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Oct. 02, 2022	Jan. 02, 2022
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 22,124	$ 19,727
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	11,355	14,487
Marketable securities	22,724	$ 17,121
Total cash, cash equivalents and current marketable securities, Carrying Amount	34,128
Total cash, cash equivalents and current marketable securities, Unrecognized Loss	(54)
Total cash, cash equivalents and current marketable securities, Estimated Fair Value	34,074
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	11,955
Held-to-maturity Securities, Unrecognized Loss	(5)
Held-to-maturity Securities - Estimated Fair Value	11,950
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	9,111
Marketable securities	2,844
Held-to-maturity Securities | Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	4,037
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	4,037
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	4,037
Marketable securities	0
Held-to-maturity Securities | Non-U.S. sovereign securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	389
Held-to-maturity Securities, Unrecognized Loss
Held-to-maturity Securities - Estimated Fair Value	389
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	89
Marketable securities	300
Held-to-maturity Securities | U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,541
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,541
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,541
Marketable securities	0
Held-to-maturity Securities | Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,544
Held-to-maturity Securities, Unrecognized Loss	(5)
Held-to-maturity Securities - Estimated Fair Value	2,539
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents
Marketable securities	2,544
Held-to-maturity Securities | Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,516
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,516
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,516
Marketable securities	0
Held-to-maturity Securities | Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	928
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	928
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	928
Marketable securities	0
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	22,173
Available-for-sale Securities, Unrecognized Loss	(49)
Available-for-sale Securities - Estimated Fair Value	22,124
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,244
Marketable securities	19,880
Available-for-sale Securities | U.S. Gov't securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	21,930
Available-for-sale Securities, Unrecognized Loss	(48)
Available-for-sale Securities - Estimated Fair Value	21,882
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	243
Available-for-sale Securities, Unrecognized Loss	(1)
Available-for-sale Securities - Estimated Fair Value	242
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	55
Marketable securities	187
Available-for-sale Securities | U.S. Gov't securities
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,189
Marketable securities	$ 19,693

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Oct. 02, 2022 USD ($)
Cost Basis
Due within one year	$ 22,153
Due after one year through five years	20
Due after five years through ten years	0
Total debt securities	22,173
Fair Value
Due within one year	22,104
Due after one year through five years	20
Due after five years through ten years	0
Total debt securities	$ 22,124

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)	Oct. 02, 2022 USD ($)	Oct. 02, 2022 EUR (€)	Oct. 02, 2022 GBP (£)	Jan. 02, 2022 USD ($)
Financial Liabilities
Current Debt	$ 4,424,000,000			$ 3,766,000,000
Non-Current Debt
Non-Current Debt	27,603,000,000			$ 29,985,000,000
Carrying Amount
Financial Liabilities
Current Debt	4,424,000,000
Non-Current Debt
Non-Current Debt	27,603,000,000
Estimated Fair Value
Financial Liabilities
Current Debt	4,422,000,000
Non-Current Debt
Non-Current Debt	$ 24,232,000,000
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%	6.73%	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250,000,000
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 256,000,000
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%	3.375%	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 802,000,000
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 797,000,000
0.650% Notes due 2024 (750MM Euro 0.9712)
Non-Current Debt
Stated interest rate (as a percent)	0.65%	0.65%	0.65%
Debt instrument, face amount | €		€ 750,000,000
Foreign exchange rate	0.9712	0.9712	0.9712
0.650% Notes due 2024 (750MM Euro 0.9712) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 722,000,000
0.650% Notes due 2024 (750MM Euro 0.9712) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 702,000,000
5.50% Notes due 2024 (500MM GBP 1.0908)
Non-Current Debt
Stated interest rate (as a percent)	5.50%	5.50%	5.50%
Debt instrument, face amount | £			£ 500,000,000
Foreign exchange rate	1.0908	1.0908	1.0908
5.50% Notes due 2024 (500MM GBP 1.0908) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 544,000,000
5.50% Notes due 2024 (500MM GBP 1.0908) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 548,000,000
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%	2.625%	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 749,000,000
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	721,000,000
0.55% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	922,000,000
0.55% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 826,000,000
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%	2.45%	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,996,000,000
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,868,000,000
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%	2.95%	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 877,000,000
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 829,000,000
0.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	0.95%	0.95%	0.95%
0.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,396,000,000
0.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,185,000,000
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%	2.90%	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,496,000,000
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,379,000,000
1.150% Notes due 2028 (750MM Euro 0.9712)
Non-Current Debt
Stated interest rate (as a percent)	1.15%	1.15%	1.15%
Debt instrument, face amount | €		€ 750,000,000
Foreign exchange rate	0.9712	0.9712	0.9712
1.150% Notes due 2028 (750MM Euro 0.9712) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 724,000,000
1.150% Notes due 2028 (750MM Euro 0.9712) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 649,000,000
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%	6.95%	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 298,000,000
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 342,000,000
1.30% Notes due 2030
Non-Current Debt
Stated interest rate (as a percent)	1.30%	1.30%	1.30%
1.30% Notes due 2030 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,606,000,000
1.30% Notes due 2030 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,276,000,000
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%	4.95%	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498,000,000
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 507,000,000
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%	4.375%	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 855,000,000
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	820,000,000
1.650% Notes due 2035 (1.5B Euro 0.9712) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,450,000,000
Stated interest rate (as a percent)	1.65%	1.65%	1.65%
Debt instrument, face amount	$ 1,500,000,000
Foreign exchange rate	0.9712	0.9712	0.9712
1.650% Notes due 2035 (1.5B Euro 0.9712) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,181,000,000
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%	3.55%	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 841,000,000
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 726,000,000
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%	5.95%	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 993,000,000
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,074,000,000
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%	3.625%	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,334,000,000
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,154,000,000
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%	3.40%	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992,000,000
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 822,000,000
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%	5.85%	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 697,000,000
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 747,000,000
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%	4.50%	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 540,000,000
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 506,000,000
2.10% Notes due 2040
Non-Current Debt
Stated interest rate (as a percent)	2.10%	2.10%	2.10%
2.10% Notes due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 827,000,000
2.10% Notes due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 551,000,000
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%	4.85%	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297,000,000
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 291,000,000
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%	4.50%	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 496,000,000
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 457,000,000
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%	3.70%	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,976,000,000
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,626,000,000
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%	3.75%	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 811,000,000
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 668,000,000
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%	3.50%	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 743,000,000
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 593,000,000
2.25% Notes due 2050
Non-Current Debt
Stated interest rate (as a percent)	2.25%	2.25%	2.25%
2.25% Notes due 2050 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 809,000,000
2.25% Notes due 2050 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 500,000,000
2.45% Notes due 2060
Non-Current Debt
Stated interest rate (as a percent)	2.45%	2.45%	2.45%
2.45% Notes due 2060 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,054,000,000
2.45% Notes due 2060 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	619,000,000
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	8,000,000
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 12,000,000

Income Taxes (Details)

Income Taxes (Details) $ in Billions	3 Months Ended	9 Months Ended
	Oct. 03, 2021 USD ($)	Oct. 02, 2022 USD ($)	Oct. 03, 2021 USD ($)
Income Tax Disclosure [Abstract]
Worldwide effective income tax rate (as a percent)		17.70%	10%
Deferred tax asset	$ 2.3		$ 2.3
Deferred tax liability	1.7		1.7
Deferred tax benefit, net	0.6		$ 0.6
Decrease in effective tax rate (percent)			3.40%
Unrecognized tax benefits		$ 3.8
Income Tax Contingency
Incremental tax costs related to restructuring		$ 0.4
Incremental change to income tax rate (percent)		2%
Favorable tax event (percent)			1%
Auris Health | Purchased In-Process Research And Development
Income Tax Contingency
Impairment of intangible assets	$ 0.9
Effective income tax rate, impairment losses, percent	22.40%
Talc | CONSUMER HEALTH (1)
Income Tax Contingency
Litigation expense	$ 1.4
Effective tax rate for legal expense (percent)	0.235
Risperdal | CONSUMER HEALTH (1)
Income Tax Contingency
Litigation expense	$ 0.8
Effective tax rate for legal expense (percent)	0.164

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 313	$ 339	$ 953	$ 1,019
Interest cost	226	192	685	578
Expected return on plan assets	(683)	(661)	(2,075)	(1,988)
Amortization of prior service cost/(credit)	(46)	(46)	(138)	(136)
Recognized actuarial losses	163	314	492	944
Curtailments and settlements	0	0	1	1
Net periodic benefit cost	(27)	138	(82)	418
Other Benefit Plans
Components of net periodic benefit cost
Service cost	80	78	240	232
Interest cost	26	20	79	61
Expected return on plan assets	(2)	(1)	(6)	(5)
Amortization of prior service cost/(credit)	(1)	(8)	(4)	(23)
Recognized actuarial losses	30	38	91	113
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 133	$ 127	$ 400	$ 378

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	9 Months Ended
	Oct. 02, 2022 USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 82
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 15

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 76,357	$ 69,580	$ 74,023	$ 63,278
Net change	(1,449)	(315)	(2,234)	(173)
Ending Balance	74,599	70,272	74,599	70,272
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(10,017)
Ending Balance	(11,974)		(11,974)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(3)
Ending Balance	(38)		(38)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(2,702)
Ending Balance	(2,358)		(2,358)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(336)
Ending Balance	(922)		(922)
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(13,843)	(15,100)	(13,058)	(15,242)
Net change	(1,449)	(315)	(2,234)	(173)
Ending Balance	$ (15,292)	$ (15,415)	$ (15,292)	$ (15,415)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares shares in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.70	$ 1.39	$ 5.49	$ 6.13
Average shares outstanding — basic	2,627.9	2,632.6	2,628.9	2,632.2
Potential shares exercisable under stock option plans	140.1	138.3	141.1	139.1
Less: shares which could be repurchased under treasury stock method	(106.7)	(96)	(102.5)	(96.7)
Average shares outstanding — diluted	2,661.3	2,674.9	2,667.5	2,674.6
Diluted net earnings per share	$ 1.68	$ 1.37	$ 5.41	$ 6.04

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Sales by segment of business
Sales to customers	$ 23,791	$ 23,338	$ 71,237	$ 68,971
Percent Change (as a percent)	1.90%		3.30%
U.S.
Sales by segment of business
Sales to customers	$ 12,453	11,963	$ 36,064	34,993
Percent Change (as a percent)	4.10%		3.10%
International
Sales by segment of business
Sales to customers	$ 11,338	11,375	$ 35,173	33,978
Percent Change (as a percent)	(0.30%)		3.50%
CONSUMER HEALTH (1)
Sales by segment of business
Sales to customers	$ 3,795	3,812	$ 11,186	11,307
Percent Change (as a percent)	(0.40%)		(1.10%)
CONSUMER HEALTH (1) | U.S.
Sales by segment of business
Sales to customers	$ 1,659	1,625	$ 4,903	4,987
Percent Change (as a percent)	2.10%		(1.70%)
CONSUMER HEALTH (1) | International
Sales by segment of business
Sales to customers	$ 2,136	2,187	$ 6,283	6,320
Percent Change (as a percent)	(2.30%)		(0.60%)
CONSUMER HEALTH (1) | OTC [Member]
Sales by segment of business
Sales to customers	$ 1,519	1,484	$ 4,462	4,183
Percent Change (as a percent)	2.50%		6.70%
CONSUMER HEALTH (1) | OTC [Member] | U.S.
Sales by segment of business
Sales to customers	$ 695	686	$ 2,028	1,960
Percent Change (as a percent)	1.40%		3.50%
CONSUMER HEALTH (1) | OTC [Member] | International
Sales by segment of business
Sales to customers	$ 825	798	$ 2,434	2,223
Percent Change (as a percent)	3.40%		9.50%
CONSUMER HEALTH (1) | Skin Health/Beauty
Sales by segment of business
Sales to customers	$ 1,126	1,124	$ 3,264	3,457
Percent Change (as a percent)	0.10%		(5.60%)
CONSUMER HEALTH (1) | Skin Health/Beauty | U.S.
Sales by segment of business
Sales to customers	$ 591	569	$ 1,764	1,862
Percent Change (as a percent)	3.70%		(5.30%)
CONSUMER HEALTH (1) | Skin Health/Beauty | International
Sales by segment of business
Sales to customers	$ 535	555	$ 1,500	1,595
Percent Change (as a percent)	(3.60%)		(6.00%)
CONSUMER HEALTH (1) | Oral Care
Sales by segment of business
Sales to customers	$ 375	398	$ 1,135	1,240
Percent Change (as a percent)	(5.80%)		(8.50%)
CONSUMER HEALTH (1) | Oral Care | U.S.
Sales by segment of business
Sales to customers	$ 158	150	$ 471	478
Percent Change (as a percent)	5.20%		(1.50%)
CONSUMER HEALTH (1) | Oral Care | International
Sales by segment of business
Sales to customers	$ 217	248	$ 664	762
Percent Change (as a percent)	(12.40%)		(12.80%)
CONSUMER HEALTH (1) | Baby Care
Sales by segment of business
Sales to customers	$ 375	391	$ 1,105	1,167
Percent Change (as a percent)	(4.30%)		(5.40%)
CONSUMER HEALTH (1) | Baby Care | U.S.
Sales by segment of business
Sales to customers	$ 91	95	$ 264	288
Percent Change (as a percent)	(4.00%)		(8.20%)
CONSUMER HEALTH (1) | Baby Care | International
Sales by segment of business
Sales to customers	$ 283	296	$ 840	879
Percent Change (as a percent)	(4.50%)		(4.40%)
CONSUMER HEALTH (1) | Women's Health
Sales by segment of business
Sales to customers	$ 225	232	$ 684	684
Percent Change (as a percent)	(3.00%)		(0.10%)
CONSUMER HEALTH (1) | Women's Health | U.S.
Sales by segment of business
Sales to customers	$ 2	3	$ 9	9
Percent Change (as a percent)	(22.00%)		(2.80%)
CONSUMER HEALTH (1) | Women's Health | International
Sales by segment of business
Sales to customers	$ 222	229	$ 674	675
Percent Change (as a percent)	(2.70%)		(0.10%)
CONSUMER HEALTH (1) | Wound Care/Other
Sales by segment of business
Sales to customers	$ 176	182	$ 537	575
Percent Change (as a percent)	(3.90%)		(6.70%)
CONSUMER HEALTH (1) | Wound Care/Other | U.S.
Sales by segment of business
Sales to customers	$ 122	122	$ 366	390
Percent Change (as a percent)	(0.20%)		(6.00%)
CONSUMER HEALTH (1) | Wound Care/Other | International
Sales by segment of business
Sales to customers	$ 53	61	$ 170	186
Percent Change (as a percent)	(11.40%)		(8.20%)
PHARMACEUTICAL(1)
Sales by segment of business
Sales to customers	$ 13,214	12,882	$ 39,400	37,463
Percent Change (as a percent)	2.60%		5.20%
PHARMACEUTICAL(1) | U.S.
Sales by segment of business
Sales to customers	$ 7,438	7,221	$ 21,229	20,536
Percent Change (as a percent)	3%		3.40%
PHARMACEUTICAL(1) | International
Sales by segment of business
Sales to customers	$ 5,776	5,661	$ 18,171	16,927
Percent Change (as a percent)	2%		7.30%
PHARMACEUTICAL(1) | Immunology
Sales by segment of business
Sales to customers	$ 4,287	4,250	$ 12,817	12,395
Percent Change (as a percent)	0.90%		3.40%
PHARMACEUTICAL(1) | Immunology | U.S.
Sales by segment of business
Sales to customers	$ 2,876	2,771	$ 8,230	7,932
Percent Change (as a percent)	3.80%		3.80%
PHARMACEUTICAL(1) | Immunology | International
Sales by segment of business
Sales to customers	$ 1,411	1,480	$ 4,587	4,464
Percent Change (as a percent)	(4.70%)		2.80%
PHARMACEUTICAL(1) | Immunology | REMICADE
Sales by segment of business
Sales to customers	$ 558	761	$ 1,868	2,426
Percent Change (as a percent)	(26.60%)		(23.00%)
PHARMACEUTICAL(1) | Immunology | REMICADE | U.S.
Sales by segment of business
Sales to customers	$ 350	480	$ 1,099	1,508
Percent Change (as a percent)	(27.00%)		(27.10%)
PHARMACEUTICAL(1) | Immunology | REMICADE | U.S. Exports
Sales by segment of business
Sales to customers	$ 39	47	$ 163	197
Percent Change (as a percent)	(16.90%)		(17.20%)
PHARMACEUTICAL(1) | Immunology | REMICADE | International
Sales by segment of business
Sales to customers	$ 169	234	$ 606	721
Percent Change (as a percent)	(27.80%)		(16.00%)
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA
Sales by segment of business
Sales to customers	$ 545	571	$ 1,682	1,717
Percent Change (as a percent)	(4.60%)		(2.00%)
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | U.S.
Sales by segment of business
Sales to customers	$ 298	295	$ 886	840
Percent Change (as a percent)	0.90%		5.40%
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | International
Sales by segment of business
Sales to customers	$ 248	276	$ 797	877
Percent Change (as a percent)	(10.40%)		(9.20%)
PHARMACEUTICAL(1) | Immunology | STELARA
Sales by segment of business
Sales to customers	$ 2,449	2,378	$ 7,336	6,800
Percent Change (as a percent)	3%		7.90%
PHARMACEUTICAL(1) | Immunology | STELARA | U.S.
Sales by segment of business
Sales to customers	$ 1,655	1,569	$ 4,766	4,396
Percent Change (as a percent)	5.50%		8.40%
PHARMACEUTICAL(1) | Immunology | STELARA | International
Sales by segment of business
Sales to customers	$ 794	809	$ 2,571	2,404
Percent Change (as a percent)	(1.90%)		6.90%
PHARMACEUTICAL(1) | Immunology | TREMFYA
Sales by segment of business
Sales to customers	$ 729	537	$ 1,916	1,434
Percent Change (as a percent)	35.90%		33.60%
PHARMACEUTICAL(1) | Immunology | TREMFYA | U.S.
Sales by segment of business
Sales to customers	$ 530	376	$ 1,303	975
Percent Change (as a percent)	40.70%		33.60%
PHARMACEUTICAL(1) | Immunology | TREMFYA | International
Sales by segment of business
Sales to customers	$ 200	161	$ 613	459
Percent Change (as a percent)	24.60%		33.70%
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 5	3	$ 14	18
Percent Change (as a percent)			(19.30%)
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales to customers	5	3	$ 14	15
Percent Change (as a percent)			(3.50%)
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales to customers	0	0	$ 0	3
PHARMACEUTICAL(1) | Infectious Diseases
Sales by segment of business
Sales to customers	$ 1,295	1,378	$ 3,908	3,394
Percent Change (as a percent)	(6.00%)		15.20%
PHARMACEUTICAL(1) | Infectious Diseases | U.S.
Sales by segment of business
Sales to customers	$ 390	679	$ 1,266	1,635
Percent Change (as a percent)	(42.70%)		(22.60%)
PHARMACEUTICAL(1) | Infectious Diseases | International
Sales by segment of business
Sales to customers	$ 905	698	$ 2,642	1,758
Percent Change (as a percent)	29.70%		50.30%
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19
Sales by segment of business
Sales to customers	$ 489	502	$ 1,490	766
Percent Change (as a percent)	(2.70%)
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | U.S.
Sales by segment of business
Sales to customers	$ 0	270	$ 120	421
Percent Change (as a percent)			(71.50%)
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | International
Sales by segment of business
Sales to customers	489	233	$ 1,370	346
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine
Sales by segment of business
Sales to customers	$ 245	259	$ 718	764
Percent Change (as a percent)	(5.20%)		(6.10%)
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | U.S.
Sales by segment of business
Sales to customers	$ 9	12	$ 27	31
Percent Change (as a percent)	(27.10%)		(14.50%)
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | International
Sales by segment of business
Sales to customers	$ 237	247	$ 691	733
Percent Change (as a percent)	(4.20%)		(5.70%)
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
Sales by segment of business
Sales to customers	$ 485	517	$ 1,450	1,568
Percent Change (as a percent)	(6.40%)		(7.50%)
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S.
Sales by segment of business
Sales to customers	$ 372	380	$ 1,096	1,128
Percent Change (as a percent)	(2.20%)		(2.90%)
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International
Sales by segment of business
Sales to customers	$ 112	137	$ 354	440
Percent Change (as a percent)	(17.90%)		(19.50%)
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES(
Sales by segment of business
Sales to customers	$ 77	99	$ 251	295
Percent Change (as a percent)	(22.40%)		(14.80%)
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S.
Sales by segment of business
Sales to customers	$ 10	18	$ 24	55
Percent Change (as a percent)	(46.40%)		(57.20%)
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International
Sales by segment of business
Sales to customers	$ 68	82	$ 228	240
Percent Change (as a percent)	(17.10%)		(5.00%)
PHARMACEUTICAL(1) | Neuroscience
Sales by segment of business
Sales to customers	$ 1,681	1,680	$ 5,156	5,199
Percent Change (as a percent)	0%		(0.80%)
PHARMACEUTICAL(1) | Neuroscience | U.S.
Sales by segment of business
Sales to customers	$ 919	835	$ 2,658	2,448
Percent Change (as a percent)	10%		8.60%
PHARMACEUTICAL(1) | Neuroscience | International
Sales by segment of business
Sales to customers	$ 763	845	$ 2,498	2,751
Percent Change (as a percent)	(9.90%)		(9.20%)
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate
Sales by segment of business
Sales to customers	$ 158	157	$ 476	489
Percent Change (as a percent)	0.80%		(2.50%)
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | U.S.
Sales by segment of business
Sales to customers	$ 41	35	$ 114	117
Percent Change (as a percent)	19.30%		(2.20%)
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | International
Sales by segment of business
Sales to customers	$ 117	122	$ 362	372
Percent Change (as a percent)	(4.40%)		(2.60%)
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
Sales by segment of business
Sales to customers	$ 1,031	1,004	$ 3,132	2,994
Percent Change (as a percent)	2.60%		4.60%
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.
Sales by segment of business
Sales to customers	$ 684	648	$ 2,036	1,882
Percent Change (as a percent)	5.30%		8.10%
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International
Sales by segment of business
Sales to customers	$ 348	355	$ 1,097	1,111
Percent Change (as a percent)	(2.30%)		(1.30%)
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA
Sales by segment of business
Sales to customers	$ 119	140	$ 373	452
Percent Change (as a percent)	(14.90%)		(17.40%)
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | U.S.
Sales by segment of business
Sales to customers	$ 67	71	$ 195	210
Percent Change (as a percent)	(6.10%)		(7.10%)
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | International
Sales by segment of business
Sales to customers	$ 52	69	$ 178	242
Percent Change (as a percent)	(24.20%)		(26.30%)
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 374	379	$ 1,174	1,265
Percent Change (as a percent)	(1.90%)		(7.30%)
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales to customers	$ 127	81	$ 313	239
Percent Change (as a percent)	57.20%		31.10%
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales to customers	$ 246	298	$ 861	1,026
Percent Change (as a percent)	(17.90%)		(16.20%)
PHARMACEUTICAL(1) | Oncology
Sales by segment of business
Sales to customers	$ 4,064	3,665	$ 12,056	10,770
Percent Change (as a percent)	10.90%		11.90%
PHARMACEUTICAL(1) | Oncology | U.S.
Sales by segment of business
Sales to customers	$ 1,812	1,525	$ 5,073	4,364
Percent Change (as a percent)	18.80%		16.20%
PHARMACEUTICAL(1) | Oncology | International
Sales by segment of business
Sales to customers	$ 2,252	2,140	$ 6,983	6,406
Percent Change (as a percent)	5.20%		9%
PHARMACEUTICAL(1) | Oncology | DARZALEX
Sales by segment of business
Sales to customers	$ 2,052	1,580	$ 5,894	4,378
Percent Change (as a percent)	29.80%		34.60%
PHARMACEUTICAL(1) | Oncology | DARZALEX | U.S.
Sales by segment of business
Sales to customers	$ 1,097	841	$ 3,071	2,302
Percent Change (as a percent)	30.30%		33.40%
PHARMACEUTICAL(1) | Oncology | DARZALEX | International
Sales by segment of business
Sales to customers	$ 955	739	$ 2,823	2,076
Percent Change (as a percent)	29.30%		36%
PHARMACEUTICAL(1) | Oncology | ERLEADA
Sales by segment of business
Sales to customers	$ 490	344	$ 1,340	907
Percent Change (as a percent)	42.20%		47.70%
PHARMACEUTICAL(1) | Oncology | ERLEADA | U.S.
Sales by segment of business
Sales to customers	$ 254	214	$ 693	578
Percent Change (as a percent)	19.10%		20%
PHARMACEUTICAL(1) | Oncology | ERLEADA | International
Sales by segment of business
Sales to customers	$ 235	130	$ 647	329
PHARMACEUTICAL(1) | Oncology | IMBRUVICA
Sales by segment of business
Sales to customers	$ 911	1,066	$ 2,918	3,307
Percent Change (as a percent)	(14.60%)		(11.80%)
PHARMACEUTICAL(1) | Oncology | IMBRUVICA | U.S.
Sales by segment of business
Sales to customers	$ 353	413	$ 1,072	1,311
Percent Change (as a percent)	(14.60%)		(18.30%)
PHARMACEUTICAL(1) | Oncology | IMBRUVICA | International
Sales by segment of business
Sales to customers	$ 559	654	$ 1,847	1,996
Percent Change (as a percent)	(14.60%)		(7.50%)
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate
Sales by segment of business
Sales to customers	$ 456	548	$ 1,500	1,749
Percent Change (as a percent)	(16.70%)		(14.20%)
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | U.S.
Sales by segment of business
Sales to customers	$ 16	25	$ 54	96
Percent Change (as a percent)	(33.10%)		(43.40%)
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | International
Sales by segment of business
Sales to customers	$ 440	523	$ 1,446	1,653
Percent Change (as a percent)	(15.90%)		(12.50%)
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY
Sales by segment of business
Sales to customers	$ 155	126	$ 403	428
Percent Change (as a percent)	23.10%		(5.90%)
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 92	32	$ 183	76
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | International
Sales by segment of business
Sales to customers	$ 64	94	$ 220	352
Percent Change (as a percent)	(32.10%)		(37.50%)
PHARMACEUTICAL(1) | Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 852	868	$ 2,547	2,599
Percent Change (as a percent)	(1.90%)		(2.00%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales to customers	$ 604	610	$ 1,736	1,778
Percent Change (as a percent)	(1.10%)		(2.40%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | International
Sales by segment of business
Sales to customers	$ 247	258	$ 810	821
Percent Change (as a percent)	(3.80%)		(1.30%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT
Sales by segment of business
Sales to customers	$ 441	458	$ 1,322	1,371
Percent Change (as a percent)	(3.90%)		(3.60%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | U.S.
Sales by segment of business
Sales to customers	$ 289	299	$ 827	861
Percent Change (as a percent)	(3.40%)		(4.00%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | International
Sales by segment of business
Sales to customers	$ 152	159	$ 495	510
Percent Change (as a percent)	(4.70%)		(3.00%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI
Sales by segment of business
Sales to customers	$ 333	309	$ 986	927
Percent Change (as a percent)	7.70%		6.30%
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | U.S.
Sales by segment of business
Sales to customers	$ 283	265	$ 824	792
Percent Change (as a percent)	6.60%		3.90%
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | International
Sales by segment of business
Sales to customers	$ 50	44	$ 162	135
Percent Change (as a percent)	14.20%		20.40%
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other
Sales by segment of business
Sales to customers	$ 78	101	$ 239	301
Percent Change (as a percent)	(22.10%)		(20.50%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | U.S.
Sales by segment of business
Sales to customers	$ 33	47	$ 86	125
Percent Change (as a percent)	(29.50%)		(31.30%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | International
Sales by segment of business
Sales to customers	$ 46	54	$ 154	176
Percent Change (as a percent)	(15.70%)		(13.00%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 1,034	1,041	$ 2,916	3,106
Percent Change (as a percent)	(0.60%)		(6.10%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales to customers	$ 837	800	$ 2,266	2,379
Percent Change (as a percent)	4.50%		(4.80%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales to customers	$ 198	241	$ 651	727
Percent Change (as a percent)	(17.50%)		(10.40%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO
Sales by segment of business
Sales to customers	$ 689	636	$ 1,806	1,794
Percent Change (as a percent)	8.40%		0.70%
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | U.S.
Sales by segment of business
Sales to customers	$ 689	636	$ 1,806	1,794
Percent Change (as a percent)	8.40%		0.70%
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | International
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0%		0%
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET
Sales by segment of business
Sales to customers	$ 109	133	$ 357	443
Percent Change (as a percent)	(18.40%)		(19.50%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | U.S.
Sales by segment of business
Sales to customers	$ 49	66	$ 164	249
Percent Change (as a percent)	(25.80%)		(34.10%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | International
Sales by segment of business
Sales to customers	$ 60	67	$ 193	194
Percent Change (as a percent)	(11.00%)		(0.60%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other
Sales by segment of business
Sales to customers	$ 236	271	$ 753	869
Percent Change (as a percent)	(12.80%)		(13.30%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | U.S.
Sales by segment of business
Sales to customers	$ 98	98	$ 295	336
Percent Change (as a percent)	(0.10%)		(12.20%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | International
Sales by segment of business
Sales to customers	$ 138	173	$ 458	533
Percent Change (as a percent)	(20.00%)		(14.00%)
MEDTECH(3)
Sales by segment of business
Sales to customers	$ 6,782	6,644	$ 20,651	20,201
Percent Change (as a percent)	2.10%		2.20%
MEDTECH(3) | U.S.
Sales by segment of business
Sales to customers	$ 3,356	3,117	$ 9,932	9,470
Percent Change (as a percent)	7.70%		4.90%
MEDTECH(3) | International
Sales by segment of business
Sales to customers	$ 3,426	3,527	$ 10,719	10,731
Percent Change (as a percent)	(2.90%)		(0.10%)
MEDTECH(3) | Interventional Solutions
Sales by segment of business
Sales to customers	$ 1,060	957	$ 3,202	2,952
Percent Change (as a percent)	10.80%		8.50%
MEDTECH(3) | Interventional Solutions | U.S.
Sales by segment of business
Sales to customers	$ 547	444	$ 1,566	1,353
Percent Change (as a percent)	23.20%		15.70%
MEDTECH(3) | Interventional Solutions | International
Sales by segment of business
Sales to customers	$ 513	513	$ 1,636	1,599
Percent Change (as a percent)	0%		2.30%
MEDTECH(3) | Orthopaedics
Sales by segment of business
Sales to customers	$ 2,095	2,093	$ 6,440	6,433
Percent Change (as a percent)	0.10%		0.10%
MEDTECH(3) | Orthopaedics | U.S.
Sales by segment of business
Sales to customers	$ 1,309	1,249	$ 3,936	3,821
Percent Change (as a percent)	4.80%		3%
MEDTECH(3) | Orthopaedics | International
Sales by segment of business
Sales to customers	$ 785	843	$ 2,504	2,611
Percent Change (as a percent)	(6.90%)		(4.10%)
MEDTECH(3) | Orthopaedics | HIPS
Sales by segment of business
Sales to customers	$ 352	355	$ 1,129	1,102
Percent Change (as a percent)	(0.90%)		2.50%
MEDTECH(3) | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales to customers	$ 228	209	$ 693	651
Percent Change (as a percent)	9.10%		6.50%
MEDTECH(3) | Orthopaedics | HIPS | International
Sales by segment of business
Sales to customers	$ 124	146	$ 437	451
Percent Change (as a percent)	(15.10%)		(3.30%)
MEDTECH(3) | Orthopaedics | KNEES
Sales by segment of business
Sales to customers	$ 317	316	$ 1,005	983
Percent Change (as a percent)	0.40%		2.30%
MEDTECH(3) | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales to customers	$ 203	184	$ 620	579
Percent Change (as a percent)	9.80%		6.90%
MEDTECH(3) | Orthopaedics | KNEES | International
Sales by segment of business
Sales to customers	$ 115	131	$ 386	403
Percent Change (as a percent)	(12.80%)		(4.40%)
MEDTECH(3) | Orthopaedics | TRAUMA
Sales by segment of business
Sales to customers	$ 717	715	$ 2,161	2,157
Percent Change (as a percent)	0.20%		0.20%
MEDTECH(3) | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales to customers	$ 473	455	$ 1,412	1,352
Percent Change (as a percent)	3.80%		4.40%
MEDTECH(3) | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales to customers	$ 244	260	$ 749	805
Percent Change (as a percent)	(6.00%)		(7.00%)
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER
Sales by segment of business
Sales to customers	$ 708	706	$ 2,144	2,190
Percent Change (as a percent)	0.30%		(2.10%)
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | U.S.
Sales by segment of business
Sales to customers	$ 406	401	$ 1,211	1,239
Percent Change (as a percent)	1.30%		(2.20%)
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | International
Sales by segment of business
Sales to customers	$ 303	306	$ 933	952
Percent Change (as a percent)	(1.10%)		(2.00%)
MEDTECH(3) | Surgery
Sales by segment of business
Sales to customers	$ 2,422	2,405	$ 7,306	7,299
Percent Change (as a percent)	0.70%		0.10%
MEDTECH(3) | Surgery | U.S.
Sales by segment of business
Sales to customers	$ 984	948	$ 2,897	2,881
Percent Change (as a percent)	3.70%		0.50%
MEDTECH(3) | Surgery | International
Sales by segment of business
Sales to customers	$ 1,439	1,457	$ 4,410	4,418
Percent Change (as a percent)	(1.20%)		(0.20%)
MEDTECH(3) | Surgery | ADVANCED
Sales by segment of business
Sales to customers	$ 1,158	1,144	$ 3,460	3,430
Percent Change (as a percent)	1.20%		0.90%
MEDTECH(3) | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales to customers	$ 457	440	$ 1,328	1,304
Percent Change (as a percent)	3.80%		1.80%
MEDTECH(3) | Surgery | ADVANCED | International
Sales by segment of business
Sales to customers	$ 701	705	$ 2,132	2,126
Percent Change (as a percent)	(0.40%)		0.30%
MEDTECH(3) | Surgery | GENERAL
Sales by segment of business
Sales to customers	$ 1,264	1,261	$ 3,846	3,869
Percent Change (as a percent)	0.30%		(0.60%)
MEDTECH(3) | Surgery | GENERAL | U.S.
Sales by segment of business
Sales to customers	$ 527	508	$ 1,569	1,577
Percent Change (as a percent)	3.60%		(0.50%)
MEDTECH(3) | Surgery | GENERAL | International
Sales by segment of business
Sales to customers	$ 737	752	$ 2,277	2,292
Percent Change (as a percent)	(2.00%)		(0.60%)
MEDTECH(3) | Vision
Sales by segment of business
Sales to customers	$ 1,206	1,189	$ 3,704	3,517
Percent Change (as a percent)	1.40%		5.30%
MEDTECH(3) | Vision | U.S.
Sales by segment of business
Sales to customers	$ 517	475	$ 1,534	1,414
Percent Change (as a percent)	8.80%		8.50%
MEDTECH(3) | Vision | International
Sales by segment of business
Sales to customers	$ 689	714	$ 2,170	2,103
Percent Change (as a percent)	(3.50%)		3.20%
MEDTECH(3) | Vision | CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 908	882	$ 2,712	2,607
Percent Change (as a percent)	3%		4%
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales to customers	$ 405	359	$ 1,179	1,082
Percent Change (as a percent)	12.60%		9%
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales to customers	$ 503	522	$ 1,533	1,525
Percent Change (as a percent)	(3.60%)		0.50%
MEDTECH(3) | Vision | SURGICAL
Sales by segment of business
Sales to customers	$ 298	308	$ 992	910
Percent Change (as a percent)	(3.20%)		9%
MEDTECH(3) | Vision | SURGICAL | U.S.
Sales by segment of business
Sales to customers	$ 112	117	$ 355	333
Percent Change (as a percent)	(3.20%)		6.80%
MEDTECH(3) | Vision | SURGICAL | International
Sales by segment of business
Sales to customers	$ 186	191	$ 637	577
Percent Change (as a percent)	(3.30%)		10.30%
CONSUMER HEALTH and PHARMACEUTICAL [Member] | OTC [Member] | CHINA
Sales by segment of business
Sales to customers		$ 100		$ 300

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Segment Reporting Information [Line Items]
Worldwide income before tax	$ 5,822	$ 3,849	$ 17,524	$ 17,940
Percentage Change in Operating Income Loss	51.30%		(2.30%)
Amount prepaid and due to manufacturers			$ 500
Restructuring charges	$ 82	60	237	169
In-process research and development	0	900	610	900
bermekimab | In-process research and development
Segment Reporting Information [Line Items]
Impairment of intangible assets			600
CONSUMER HEALTH (1) | Risperdal
Segment Reporting Information [Line Items]
Litigation expense		800
PHARMACEUTICAL(1) | Risperdal
Segment Reporting Information [Line Items]
Litigation expense		800		700
MedTech
Segment Reporting Information [Line Items]
Amortization			800	800
Restructuring charges			100	200
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 6,182	4,046	$ 18,614	18,592
Percentage Change in Operating Income Loss	52.80%		0.10%
Operating Segments | CONSUMER HEALTH (1)
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 809	(577)	$ 2,279	1,131
Business Exit Costs	249	0	619	0
Amortization	100		300	300
Litigation expense		1,400	100	1,500
Operating Segments | PHARMACEUTICAL(1)
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 4,249	4,200	$ 12,593	13,663
Percentage Change in Operating Income Loss	1.20%		(7.80%)
Amortization	$ 700	800	$ 2,200	2,500
Gain (loss) on disposition of assets			600
Unrealized gain (loss) on securities	(200)	100	(700)	200
Supply network costs	400		700
Operating Segments | MedTech
Segment Reporting Information [Line Items]
Total Segment Operating Income	1,124	423	$ 3,742	3,798
Percentage Change in Operating Income Loss			(1.50%)
Amortization	300	300
Litigation expense	200		$ 200
In-process research and development		900		900
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 111	$ 197	$ 471	$ 652

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Sales by geographic area
Sales	$ 23,791	$ 23,338	$ 71,237	$ 68,971
Percentage Change In Sales By Geographic Area	1.90%		3.30%
United States
Sales by geographic area
Sales	$ 12,453	11,963	$ 36,064	34,993
Percentage Change In Sales By Geographic Area	4.10%		3.10%
Europe
Sales by geographic area
Sales	$ 5,524	5,587	$ 17,633	16,669
Percentage Change In Sales By Geographic Area	(1.10%)		5.80%
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,562	1,500	$ 4,580	4,291
Percentage Change In Sales By Geographic Area	4.10%		6.70%
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 4,252	$ 4,288	$ 12,960	$ 13,018
Percentage Change In Sales By Geographic Area	(0.90%)		(0.40%)

Acquisitions and Divestitures -

Acquisitions and Divestitures - Narrative (Details) - Evra and Doxil $ in Billions	3 Months Ended
	Apr. 04, 2021 USD ($) brand
Business Acquisition [Line Items]
Number Of Brands | brand	2
Gain (loss) on disposition of assets | $	$ 0.6

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions

1 Months Ended

6 Months Ended

Apr. 30, 2022 USD ($)

Mar. 22, 2022 USD ($)

Oct. 31, 2021 USD ($)

Jun. 30, 2021 USD ($)

Jun. 30, 2020 USD ($)

Jan. 31, 2020 USD ($)

Oct. 31, 2019 USD ($)

Jul. 31, 2018 USD ($)

Jun. 28, 2020 USD ($)

Oct. 02, 2022 claimant patient claim cases

Sep. 30, 2021 cases

May 31, 2021 claimant cases

Oct. 31, 2020 USD ($)

Apr. 30, 2015 claim

Legal Proceeding (Textuals)

Number of pending claims | claim

60

Rasmussen Instruments, LLC

Legal Proceeding (Textuals)

Damages awarded | $

$ 20

ASR

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

180

Pinnacle Acetabular Cup System

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

1,400

Pelvic Meshes

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

9,400

Risperdal

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

1,500

XARELTO

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

600

Talc

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

40,300

Invokana

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

5

Physiomesh

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

4,800

Opioid

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

3,500

Contact Lenses

Legal Proceeding (Textuals)

Number of pending claims | claim

30

Elmiron

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

1,900

Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 6.8

$ 8,000

Pending Litigation

Legal Proceeding (Textuals)

Number of pending claims | claim

860

Loss contingency, estimate of possible loss | $

$ 4,000

$ 5,000

Loss contingency, estimate of additional possible loss | $

$ 1,000

Pending Litigation | Physiomesh

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

4,300

Number of claims within settlement agreement | cases

3,729

Number of pending claims | cases

154

3,600

DePuy ASR U.S. | Settled Litigation

Legal Proceeding (Textuals)

Number of patients in settlement | patient

10,000

Baby Powder | Talc

Legal Proceeding (Textuals)

Reserve established | $

$ 2,000

Baby Powder | Judicial Ruling | Damages from Product Defects

Legal Proceeding (Textuals)

Litigation contingency | $

$ 2,100

$ 4,700

Payments for legal settlements | $

$ 2,500

Oklahoma Attorney General vs. Johnson & Johnson and JPI | Settled Litigation

Legal Proceeding (Textuals)

Damages awarded | $

$ 465

Surgical Mesh Products Marketing | Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 302

$ 344

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 82	$ 60	$ 237	$ 169
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	123		323
Restructuring charges recorded to date	2,100		2,100
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Cost savings expected	800		800
Restructuring estimated cost	2,300		2,300
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Cost savings expected	700		700
Restructuring estimated cost	2,200		2,200
Supply Chain | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	82		237
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	13		46
Supply Chain | Other (income) expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 28		40
MedTech
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 100	$ 200

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2022	Oct. 03, 2021	Oct. 02, 2022	Oct. 03, 2021
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 82	$ 60	$ 237	$ 169
MedTech
Restructuring Reserve [Roll Forward]
Reserve balance beginning			137
Restructuring charges			323
Cash settlements			(310)
Settled non cash			(31)
Reserve balance ending	119		119
MedTech | Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning			112
Restructuring charges			0
Cash settlements			(28)
Settled non cash			0
Reserve balance ending	84		84
MedTech | Asset Write-offs/Sales
Restructuring Reserve [Roll Forward]
Reserve balance beginning			0
Restructuring charges			(4)
Cash settlements			35
Settled non cash			(31)
Reserve balance ending	0		0
MedTech | Other
Restructuring Reserve [Roll Forward]
Reserve balance beginning			25
Restructuring charges			327
Cash settlements			(317)
Settled non cash			0
Reserve balance ending	$ 35		$ 35